



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 5302

## Design and synthesis of analogues of natural products†

Martin E. Maier

In this article strategies for the design and synthesis of natural product analogues are summarized and illustrated with some selected examples. Proven strategies include diverted total synthesis (DTS), function-oriented synthesis (FOS), biology-oriented synthesis (BIOS), complexity to diversity (CtD), hybrid molecules, and biosynthesis inspired synthesis. The latter includes mutasynthesis, the synthesis of natural products encoded by silent genes, and propionate scanning. Most of the examples from our group fall in the quite general concept of DTS. Thus, in case an efficient strategy to a natural product is at hand, modifications are possible at almost any stage of a synthesis. However, even for compounds of moderate complexity, organic synthesis remains a bottle neck. Unless some method for predicting the biological activity of a designed molecule becomes available, the design and synthesis of natural product analogues will remain what it is now, namely it will largely rely on trial and error.

Received 28th January 2015,  
Accepted 23rd March 2015

DOI: 10.1039/c5ob00169b

www.rsc.org/obc

## Introduction

Natural product research represents an important part of our scientific culture. From natural products (NPs) a lot of biology could be learned. Their diverse structures have enriched the collection of known organic molecules. Studies related to their biosynthesis have provided valuable insights into genetics and enzymology. Moreover, many NPs turned out to be useful molecules or lead compounds in the fragrance, crop science or pharmaceutical industries. For the latter this is well documented. Thus, an analysis of the sources of new drugs from 1981–2010 indicated that only 36% of the new chemical entities (NCEs) were discovered without inspiration from a natural product.<sup>1</sup> Despite the obvious importance, interest in natural product isolation by the pharmaceutical industry has declined in recent years. For this, several reasons might be responsible. Certainly, natural product isolation is time consuming and elaborate. A big challenge for the discovery of new NPs is de-replication, that is, to recognize and weed out already known substances. In parallel the last decade has seen a downward trend in the NCEs per year from 2001 to 2010. According to a recent hypothesis this might be due to the heavy reliance of the industry on combinatorial chemistry.<sup>1</sup> Also, it seems that computational techniques like virtual screening are not yet able to produce good lead compounds. Basically, we are far

from the vision that a drug candidate can be produced by rational design on a computer or by virtual screening of the chemical space. We still do not know enough about molecular recognition and what it takes for a ligand to trigger a signal on a receptor. Certainly, drug discovery is much more difficult than to make a plaster of a shoe print. It is rather comparable to horse racing or football betting, where knowledge and experience are advantageous.

Therefore it might be worthwhile to reconsider natural products as the inspiration and the starting point of novel drugs.<sup>2</sup> Several papers have analyzed differences between NPs and compounds from medicinal chemistry. Thus, classical medicinal chemistry is characterized by a lot of C–N bond formation. In contrast, NP syntheses strongly rely on C–C bond forming reactions. These are often accompanied by creation of OH groups, for example through allylation or aldol reactions. As a consequence, the number of asymmetric centers is higher in NPs. In addition, most of the rings in NPs are partly or completely saturated. With regard to physicochemical or drug-like properties of NPs, an analysis by A. Ganesan of 24 NPs that became approved drugs between 1970 and 2006 revealed that these fall into two categories.<sup>3</sup> NPs of the first category adhere to the Lipinski Rule of Five. NPs of the second category just follow the  $\log P < 5$  rule and the rule regarding the number of H-bond donors  $< 5$ . The obvious advantage of NPs over non-natural molecules is that during their biosynthesis they have already interacted with different enzymes and proteins.<sup>4</sup> Accordingly, their core scaffolds can be considered privileged structures. In other words, out of all possible small organic molecules NPs only occupy certain areas of chemical space that seems predestined for interaction with proteins.

Institut für Organische Chemie, Eberhard Karls Universität Tübingen,  
Auf der Morgenstelle 18, 72076 Tübingen, Germany.

E-mail: martin.e.maier@uni-tuebingen.de

†Dedicated to Prof. Richard R. Schmidt, Univ. of Konstanz, on the occasion of his 80<sup>th</sup> birthday.



The analysis and visualization of chemical space is a topic of bioinformatics. Thus, software programmes were devised that are able to generate all theoretically possible molecules following basic rules for covalent bonds and functional groups. For example, the chemical universe database GDB-17 includes all molecules up to a size of 17 atoms considering C, N, O, S and halogens. It contains 166.4 billion molecules.<sup>5</sup> In principle this database should contain many NP-like structures. To explore such large collections of molecules, descriptors are calculated for each molecule followed by projecting multidimensional property space in lower dimensions for visualization purposes.<sup>6,7</sup> In another instance, a representative universal library spanning the small molecule chemical space was constructed from the known chemical universe by stochastic search, including mutation and crossover for generating new molecules from known ones. This library contains 8.9 million structures.<sup>8</sup> All these libraries appear useful for virtual screening and bioinformatics analysis. However, hits would still have to be synthesized in order to find out whether they show biological activity or not.

Because of the reasons mentioned above, NPs appear good starting points for analogue synthesis. Chemistry related to NPs also provides the opportunity to test new reactions and synthetic strategies. In the following we discuss strategies that have been used in the synthesis of NP analogues. Of course only representative examples could be considered, since countless papers deal with the synthesis of NP analogues.

## Diverted total synthesis (DTS)

The synthesis of NP analogues is probably as old as the field of total synthesis. In the simplest approach a NP can be converted to an analogue by modifications of its functional groups. In a total synthesis programme, modifications are possible on advanced intermediates. Moreover, total synthesis allows deep seated structural modifications by using modified building blocks in fragment-based synthesis. The term diverted total synthesis (DTS) was suggested by Danishefsky to describe this strategy.<sup>9</sup> This includes the preparation of modified NPs as probes for elucidating the mode of action.<sup>10</sup> To streamline and simplify the synthesis of NP analogues, attempts have also been made to implement solid-phase strategies.<sup>11</sup> Famous cases from the last one or two decades for diverted total synthesis include the epothilone story.<sup>12</sup> Two prominent epothilones are sagopilone (2) even though it is not marketed, and the amide analogue 3 (ixemptra), which is in clinical use. The development of carfilzomib (5) from epoxomicin (4)<sup>13</sup> or the synthesis of the powerful antibiotic eravacycline (7) taking tetracycline (6) as the lead structure (Fig. 1) can also be mentioned.<sup>14,15</sup> Related to DTS is the concept of diversity-oriented synthesis.<sup>16</sup> While the compound collections obtained by this strategy are typically different from natural products, some examples are known where NP-like structures were obtained.<sup>17</sup>




Fig. 1 Some recent examples of the synthesis of promising natural product analogues.

## Latrunculin analogues

An illustrative case for DTS was put forward by the Fürstner group in connection with the total synthesis of the two marine macrolides latrunculin A (8) and B (9) (Fig. 2).<sup>18</sup> The latrunculins were isolated from a sponge collected in the red sea.<sup>19</sup> They display a range of biological activities with the dominant one being the disruption of actin polymerization. For this






Fig. 2 Structures of the two latrunculins.


reason the latrunculins are important tools for chemical biology. Key structural features include a 16- or 14-membered macrolactone ring that contains several double bonds. The side chain features an acylthiazolidinone substituent. The keto function of **8** forms a hemiacetal with the 13-OH of the macrolactone ring. Studies on semisynthetic latrunculin analogues revealed that *N*-alkylated derivatives are inactive.<sup>20</sup> Carbonate derivatives of 17-OH (hemiacetal OH) display reduced affinity to actin.<sup>21</sup>

Due to the convergent synthetic strategy used by the Fürstner group twelve latrunculin analogues could be prepared that addressed the role of the methyl groups in the macrocyclic ring and the configurations in the thiazolidinone ring.<sup>18</sup> The general synthetic strategy, exemplified by the synthesis of latrunculin B (**9**), is shown in Scheme 1.<sup>22</sup> An aldol reaction between alkyne **10** and acetylthiazolidinone **11** followed by cleavage of the silyl protecting group and acetalization furnished pyran **12**. This key fragment was then connected with several unsaturated carboxylate salts **13**, yielding esters like **14**. Formation of the macrolactone could be realized by a ring-closing alkyne metathesis (rcam). Routine steps then led to the target molecules.

The five most active compounds, listed with decreasing microfilament activity, are shown in Fig. 3. While the activity of latrunculin A (**8**) could not be surpassed, the bis-nor-methyl-latrunculin B analogue **16** turned out to be more active than **9**.

### Spongistatin analogues

With highly complex NPs, the production of a larger collection of analogues is a rather elaborate effort. But even with smaller numbers of analogues, useful information regarding SAR can be obtained. Thus, among two analogues prepared, compound **20**, which is the E-ring dehydrated version of spongistatin 1 (**19**), was even more potent than the NP itself ( $IC_{50}$  values are given for HCT116 colon cell lines) (Fig. 4).<sup>23</sup> Compound **20** was formed as a by-product in the deprotection of a 35-OTBS ether with aqueous HF-MeCN. This example highlights the role of serendipitous discoveries in chemistry. One should note that already the NP is active in the low picomolar range. So to beat this activity is truly remarkable. In contrast the analogue with



Scheme 1 Synthetic strategy for the synthesis of natural and non-natural latrunculins. Ar = 3,5-dimethylphenyl.

a truncated side chain (ending with C46) was much less active (407 nM).


The spongistatins are bis(spiroacetal) macrolides, which were isolated from marine sponges. Their potent antitumor activity is due to inhibition of mitosis by binding in the vinca binding region of tubulin.<sup>24</sup>

Another option for DTS of complex macrolides is to replace the sections of the macrocycle that are not involved in binding to the target proteins with simpler fragments. Based on the hypothesis that the small-molecule recognition domains most likely include the more rigid parts of a macrocycle, Smith, III, *et al.* designed spongistatin analogues with a simple tether between the ABEF rings (Fig. 4).<sup>25</sup> While not as active as the NP lead, the ABEF analogue **21** still displayed nanomolar activity, for example an  $IC_{50}$  of 60.5 nM *versus* 0.06 nM (for **19**) against U937 lymphoma cells.

### Pironetin analogues

A common strategy in the design of NP analogues is to truncate or simplify the structure down to the essential elements. In a recent study, Marco *et al.* prepared four analogues of the






**Fig. 3** The most active analogues prepared by the Fürstner group together with their microfilament disrupting activity (at 10  $\mu$ M effective concentration). Abbreviations:  $\pm$  weak effect, + significant effect, ++ strong effect, +++ very strong effect (less than 20% viable cells).

NP pironetin (**22**) (Scheme 2).<sup>26</sup> Unlike many molecules that bind to microtubules, pironetin exerts its antitumor activity by binding to  $\alpha$ -tubulin and not to  $\beta$ -tubulin. Well known NPs that interact with  $\beta$ -tubulin include colchicine, paclitaxel and the epothilones. The microtubule dynamics can be disturbed either by breaking up microtubules or by stabilization them. Pironetin inhibits the assembly of tubulin to microtubules. It seems that the Lys352 residue of  $\alpha$ -tubulin adds to the enoate double bond. In addition, hydrogen bonding of Asn258 to the pyrone carbonyl and the 9-OMe group contributes to the binding. SAR studies on pironetin point to the importance of a 9-OH or 9-OMe group and a 7-OH group. The Marco group removed the alkyl groups at C4, C8 and C10, thus simplifying the syntheses significantly. The terminus of the side chain was varied in the analogues. The synthetic strategy is outlined in Scheme 2. Thus, repetitive Brown allylation reactions came to use for the creation of the three stereocenters. A final acrylate formation, followed by ring-closing metathesis (rcm) and deprotection, delivered the desired analogues.

The growth inhibitory activity of the analogues was determined on ovarian cancer cell lines (Table 1). While pironetin was highly potent, the analogues were at least three orders of magnitude less active, with  $IC_{50}$  values in the micromolar range. Cell cycle analysis indicated that analogue **26** shares a common mode of action with pironetin (**22**), whereas analogues **23–25** possibly work by another mechanism. This study shows that the omission of alkyl groups may cause a reduction of the hydrophobic contribution to binding. Moreover, a loss of conformational control may be detrimental.




**Fig. 4** Structure of (+)-spongistatin 1 (**19**) and the analogues **20** and **21**.

### Benzolactone enamide analogues

Our own work regarding the synthesis of NP analogues mainly falls in the category DTS. Thus, in cases where we found an efficient synthetic strategy for a NP, we looked for opportunities in the sequence to branch out towards analogues. An early example from our group addressed apicularen A analogues.<sup>27,28</sup> Apicularen A (**32**) is a prominent member of the benzolactone enamide class of NPs.<sup>29</sup> Besides apicularen A, the family comprises the salicylihalamides **31**, the oximidines, like **33**, and lobatamide C (**34**) (Fig. 5). Common structural features include a macrocyclic salicylate ring with an enamide side chain on the aliphatic part of the macrolactone.

The benzolactone enamides are potent inhibitors of vacuolar ( $H^+$ )-ATPases. These are multicomponent proton pumps that are responsible for acidification of single membrane intracellular compartments like endosomes and lysosomes.<sup>30</sup> Biochemical studies showed that salicylihalamide binds to the  $V_0$  domain of the proton pump.<sup>31</sup> While most of the total syntheses of apicularen A pass through a *trans* pyran prior to macrolactonization,<sup>32</sup> the strategy we developed features a macrolactonization to a 12-membered macrolactone ring followed by a transannular etherification (Scheme 3).<sup>33,34</sup> The





Scheme 2 Synthesis of pironetin analogues.

Table 1 Growth inhibitory activity of pironetin (22) and analogues determined on the A2780 ovarian cancer cell line<sup>a</sup>

Compound	IC <sub>50</sub> [μM]
Pironetin (22)	0.0062
23	39.7
24	14.1
25	9.2
26	54.7

<sup>a</sup>In this and other tables the biological activity data for the compounds are given without standard deviation.

precursor 35 does indeed show a striking similarity to the salicylilhalamide core structure.

From model studies on the transannular cyclization and from the total synthesis campaign several aldehydes could be made available. These were used for attachment of the enamide side chain *via* formation of the hemiaminal followed by dehydration as shown for the conversion of 37 to 40. In all,





Fig. 5 Structures of some prominent benzolactone enamides.




Scheme 3 Key transannular cyclization towards the core structure 36 of apicularen A.

five analogues 40, 41, 42, 43 and 44 were prepared (Scheme 4). Out of these, 40 and 41 contain the intact enamide side chain but have changes in the macrolactone core.

These compounds turned out to be quite active (Table 2). On the other hand, compounds 42, 43 and 44 feature the natural core structure but a different enamide part. These analogues were roughly three orders of magnitude less cytotoxic (Table 2). Other studies concur with these findings.<sup>35</sup> Thus, it seems that variations in the acyl part of the enamide are tolerated provided that the chain is neither too short nor too long. On the other hand, the macrolactone part seems to be less sensitive to structural modifications.





**Scheme 4** Structures of some apicularen A analogues. TASF = tris(dimethylamino)sulfonium fluoride.

For the other prominent benzolactone enamide, salicylhalamide A (**31E**), our group contributed with several approaches to the macrolactone core. These strategies are summarized in

**Table 2** Cytotoxicity values ( $IC_{50}$ , nM) of some apicularen A analogues against various cell lines







Compound	Cell line		
	L-929	KB-3-1	KB-V1
<b>32</b>	6.8	2.3	15.9
<b>40</b>	19	7.1	2.4
<b>41</b>	200	180	1360
<b>42</b>	4550	1820	9100
<b>43</b>	1800	1130	9000
<b>44</b>	770	660	1980
Sali A ( <b>31E</b> )	57	6.8	9.1

Scheme 5. The first approach relied on an intramolecular Suzuki coupling of ester **46** to macrolactone **45**. Here a diastereoselective hydroboration generated the stereocenter at C12 prior to the coupling step.<sup>36</sup> This strategy was also successful in the reverse order. Thus, hydroboration of fragment **48** followed by coupling with vinyl iodide **47** gave rise to seco compound **49**. Deprotection to the corresponding hydroxy acid set the stage for an intramolecular Mitsunobu esterification.<sup>37</sup> Possibly a more efficient strategy is to close the macrolactone ring by ring-closing metathesis. In this variant the stereocenters at C12 and C13 could be created in an efficient manner by an Evans aldol reaction.<sup>38</sup> Using this strategy for the synthesis of the aliphatic sector **51**, we prepared macrolactone **45** in very good yield.







In the case of a terminal alkyne its protection as TIPS derivative **53** was required in order to achieve good yields in the rcm reaction. But the alkynyl group allowed for a formal total synthesis of salicylhalamide A by converting it to a vinyl iodide (Scheme 6).<sup>39</sup> In addition, we prepared the pyridine substituted derivative **55** by Sonogashira cross-coupling. In a simpler substrate lacking the C12 and C13 substituents, we used the side chain alkyne for click reactions with a range of azides. This way the triazoles **56** and **57** were obtained (Scheme 6).<sup>40</sup> These analogues showed cytotoxicity in the micromolar range, pointing to the crucial role of the enamide side chain in **31E**.

The ring-closing metathesis strategy for the synthesis of salicylhalamide A (**31E**) has been pioneered by De Brabander *et al.*<sup>41,42</sup> They prepared a range of analogues where the enamides were created by nucleophilic addition to vinyl isocyanates. One of the more promising analogues, called saliphenylhalamide (**66**, SaliPhe), has been explored as a potential lead for anticancer therapy.<sup>43</sup> The methyl ketone **58** was added to aldehyde **59** in a boron-aldol reaction in a non-selective reaction (Scheme 7). The mixture was carried on through the next steps. Silylation and *syn*-selective reduction was followed by Mitsunobu esterification and ring-closing metathesis. At the stage of the phenol **63** the unwanted diastereomer could be removed by chromatography. The final steps established the enamide *via* addition of lithium phenylacetylide to the intermediate vinyl isocyanate.



**intramolecular Suzuki coupling:****intermolecular Suzuki coupling / Mitsunobu macrolactonization:****Mitsunobu esterification / ring-closing metathesis:**

**Scheme 5** Synthetic strategies developed in our group towards the synthesis of salicylhalamide congeners.



**Scheme 6** Benzotriazole analogues of salicylhalamide A prepared from an alkyne precursor by a click reaction.

In a recent paper SaliPhe and other V-ATPase inhibitors were tested as antiviral compounds.<sup>44</sup> It could be shown that V-ATPase is required for human papillomavirus (HPV) infection. Addition of inhibitors affects uncoating/disassembly but

not the process of endocytosis. If the toxicity towards the host could be controlled, the inhibition of V-ATPases might be an interesting antiviral strategy.








bond and an unsaturated side chain amide. With its biological activity and our previous experience in the synthesis of benzolactones, cruentaren A (**67**) appeared as a promising target. Up to now, four total syntheses for **67** have been published.<sup>48–51</sup>

Three of them, including our own, rely on a ring-closing alkyne metathesis<sup>52</sup> (rcam) to establish the macrocyclic ring. Major differences in these routes are in the preparation of the building blocks, a benzoic acid like **68**, and a homopropargylic alcohol such as **69**. For example, we prepared fragment **68** *via* an Evans aldol reaction forming the C9–C10 bond (Scheme 9). Here the 10-Me group came from a reduction of a carboxylic function. The other fragment **69**, featuring four stereocenters, was constructed by an aldol reaction (C15–C16) and a Marshall–Tamaru reaction. In the latter transformation a chiral allenyl metal was added to an aldehyde generating a 2-substituted butynyl structure. The triple bond was then converted *via* a hydroboration/reduction step to the hydroxyethyl moiety. The two fragments **68** and **69** were combined to give ester **70** after converting the acid **68** to the corresponding carbonyl imidazolide. Using the Schrock catalyst **71** an excellent yield for the rcam reaction could be realized. The alkyne in the macrolactone ring was kept for the elaboration of the side chain. This prevented an undesired translactonization to the six-membered lactone. Conversion of the advanced intermediate **73** to the propargylic amine **76** was followed by condensation with acid **77**. After deprotection steps, a final Lindlar hydrogenation provided cruentaren A (**67**) (Scheme 8).

The efficient route to amine **76** allowed access to sufficient material and the preparation of several amide analogues (Fig. 6).<sup>53</sup> All of them were somewhat less active with **78c** being the most potent one. This points to the importance of the hydroxyl group of the amide. Compound **83** with two triple bonds was not very active ( $IC_{50} = 11.1 \mu M$ ). The 3-OH group also significantly contributes to the biological properties as can be seen in the reduced activity of 3-OMe-cruentaren A ( $IC_{50} = 28 nM$  vs.  $0.7 nM$  for **67**).

In addition to the allylamide derivatives we also wanted to prepare enamide derivatives. Although speculative it might be that the allylamide isomerizes to an enamide that then could form a highly electrophilic acyliminium ion, similar to the benzolactone enamides. It was possible to prepare vinyl iodides by hydrozirconation and iodination. A cross-coupling reaction with the side chain amide was used to create the enamide functionality. Cleavage of the silicon protecting groups and Lindlar reduction of the triple bond furnished analog **79**. Unfortunately, the enamide did not survive the demethylation step with  $BCl_3$ . Rather under these conditions the 1,3-oxazinan-4-ones **81** and **82** were formed, respectively. Out of these, **82** showed good growth inhibitory activity ( $IC_{50} = 140 nM$ ). Enamides **79** and **80** themselves were only moderately active (Fig. 6).


The Fürstner group also prepared a range of analogues.<sup>54</sup> Among them were stereoisomers of the side chain hydroxy acid and the 9-epimer **87** (Fig. 7). In addition, the 9-deoxy analogue **89** was prepared. Among the prepared analogues **85**, **86**



**Scheme 9** Summary of the strategies towards the pyran system of neopeltolide, part 1.

and **87** were the most active ones. It seems that a hydroxyl group at C9 is quite important for the activity. Moreover, either a *syn* configuration in the amide side chain or at least the correct configuration of the secondary hydroxyl group is crucial for activity.





**Fig. 7** Structures of cruentaren A analogues prepared by the Fürstner group. IC<sub>50</sub> values (against L 929 cells) are given in brackets.

**Fig. 6** Structures of some cruentaren A analogues. The IC<sub>50</sub> values (L929 cell line,  $\mu\text{M}$ ) are given in brackets after the compound numbers.



## Neopeltolide analogues

Neopeltolide (**90**) (Fig. 8) is another macrolide for which we developed an efficient synthetic route that allowed us to prepare a range of analogues.<sup>55</sup> This macrolide was isolated from a sponge *Daedalopelta* of the Neopeltodae family.<sup>56</sup> It exhibits potent cytotoxic activity with IC<sub>50</sub> values in the nanomolar range against a number of cancer cell lines.

It is certainly not among the most complicated structures but it does pose certain challenges in constructing the macrolactone and the oxazole-containing side chain. So far, ten total syntheses of neopeltolide have been published.<sup>57</sup> The first two, by Panek and Scheidt, also corrected the initial published structure that had been misassigned at positions 11 and 13. In addition to the total syntheses at least ten formal total syntheses have been reported in the literature.<sup>58</sup> All these papers nicely illustrate the state of the art in the synthesis of 2,6-*cis*-tetrahydropyrans and the stereoselective generation of stereocenters in 1,3-distance. Schemes 9 and 10 summarize the key steps that have been used in the synthesis of the pyran ring. In several of the syntheses a Prins cyclization came to use. Other strategies feature a hetero-Diels–Alder reaction.

Regarding the mode of action of neopeltolide a major contribution came from the Kozmin group.<sup>57e</sup> Using a yeast haploinsufficiency screen the cytochrome *bc1* complex was identified as the molecular target of neopeltolide (**90**) and the related NP leucascandrolide A (**115**) (Fig. 9). Thus, these compounds interfere with the crucial energy supply chain in a cell that explains their strong toxicity. The fact that leucascandrolide A (**115**), which has a macrolactone core different from **90**, addresses the same cellular target shows that some variations in the macrolactone should be possible without a significant reduction in potency. So far several groups have contributed to SAR studies of **90**.<sup>59</sup> The key findings are highlighted in Fig. 9. Thus, the pyran as well as the intact oxazole side chain are essential for activity. They basically represent the minimal structural units. In addition, the axial orientation of the ester at C5 significantly contributes to the activity. The region bridging C7 and C3 seems to tolerate changes to some degree, for example, deletion of substituents, dehydrogenation or epimerization at C9 or C11.

Some specific analogues are shown in Fig. 10. The exact binding site in the target cytochrome however is not known.






Fig. 8 Structure of (+)-neopeltolide (**90**).


## Paterson (2008): hetero Diels–Alder reaction




## Roulland (2009): Ru(II)-catalyzed ene-yne coupling





## Florescig (2010): oxidative Prins cyclization



## Fuwa (2013): intramolecular oxa-Michael addition



## Ghosh (2013): hetero Diels–Alder reaction



Scheme 10 Summary of the strategies towards the pyran system of neopeltolide, part 2.

Due to the high toxicity, most likely neopeltolide will remain as a tool for biology. Its potential as drug is probably low owing to the toxicity.






Fig. 9 Structure of the related NP leucascandrolide (**115**) and a summary of the SAR for neopeltolide. The lower part of the figure was adapted from ref. 59d.

### Chondramide A analogues

Among natural products, those which consist of obvious sub-units are ideal for the synthesis of analogues. In this regard peptides, cyclic peptides or cyclic depsipeptides can be mentioned. The latter represent a unique class of secondary metabolites that in a way bridge the peptide with the polyketide world.<sup>60</sup> They may contain unusual amino acids like *D*-configured or *N*-methylated ones. In addition, they incorporate a hydroxyl acid from the polyketide pathway. This building block connects the peptide part giving rise to an ester bond. Some prominent examples include the jasplakinolides<sup>61</sup> (**123**) and the structurally related chondramides (Fig. 11).<sup>62</sup> While the jasplakinolides have been isolated from a marine sponge,<sup>63</sup> the chondramides were found in myxobacteria. The tripeptide segments of the jasplakinolides and the chondramides are quite similar, containing an *L*-alanine, an *N*-methyl-*D*-tryptophan and an *L*- $\beta$ -tyrosine. However, the ring sizes are different since jasplakinolide contains an 8-hydroxy acid, whereas the chondramides feature a 7-hydroxy acid. The lagunamides<sup>64</sup> and viequeamide A<sup>65</sup> (**130**) are some recent examples of cyclic depsipeptides. Both show cytotoxic properties.

For jasplakinolide several total syntheses have been described.<sup>66</sup> Most of them close the macrocyclic ring by formation of the ester or an amide bond. The Waldmann group utilized a ring-closing metathesis strategy.<sup>67</sup> The first total




Fig. 10 Representative neopeltolide analogues. The  $IC_{50}$  values were determined on the A549 cell line. Compounds **116–119** (ref. 59d), and compounds **120–122** (ref. 55).

syntheses of chondramide C were achieved by the Waldmann and Kalesse groups.<sup>68,69</sup> They also secured the stereochemistry in the  $\omega$ -hydroxy acid.

Since cyclodepsipeptides are still peptide-like, they often modulate protein–protein interactions. The potent antitumor activity of the jasplakinolides and chondramides is a consequence of their stabilizing effect on F-actin filaments.<sup>70</sup>






Fig. 11 Structures of some cyclodepsipeptides.

In our own work related to the chondramides we initially developed a concise synthesis of the  $\omega$ -hydroxy acid based on a vinylogous aldol reaction and an asymmetric alkylation.<sup>71</sup> Thereafter, we achieved a total synthesis of chondramide A.<sup>72</sup>

Unlike chondramide C which contains a  $\beta$ -tyrosine, chondramide A features a 2-methoxy- $\beta$ -tyrosine. Its configuration was determined as (2*S*,3*S*). This amino acid derivative could be prepared by a Sharpless dihydroxylation followed by a selective Mitsunobu substitution of the benzylic hydroxyl group with hydrazoic acid (Scheme 11). With the tyrosine derivative 134 and the tryptophan 131 in hand, assembly of the tripeptide segment was started. Thereafter the tripeptide acid derived from 135 was combined with the  $\omega$ -hydroxy ester 136 by Mitsunobu esterification. The synthesis could be completed with macrolactam formation in the presence of *N,N,N',N'*-tetramethyl-*O*-(benzotriazol-1-yl)uronium tetrafluoroborate (TBTU) and HOBT in reasonable yield.




With efficient routes to the building blocks and a reliable strategy for assembly and ring closure, the synthesis of chondramide A analogues was undertaken.<sup>73,74</sup> One reason was to contribute to the SAR. Another reason was to exploit differences in the actin filaments between parasites and mammalian cells. For example, in the regions of contact, sequence alignment indicated residue differences at positions 200, 270 and 272. In *Toxoplasma gondii* they are G, K and A, whereas human actin has S, M and S at these positions. Altogether, we synthesized ten chondramide A analogues where the phenolic hydroxyl group was replaced with some other substituents. Most of the analogues retained high cytotoxicity in the low nanomolar region. Among the most potent ones were the -CN, -F and -NO<sub>2</sub> substituted  $\beta$ -tyrosine analogues. The *para*-position also tolerates hydroxymethyl and hydroxyethyl substitution. On the other hand replacement of the OH group with a phenyl or carboxamide caused a reduction of activity. Scheme 12 also summarizes the SAR from the contributions of the Waldmann, Kalesse and the Maier group illustrated with jasplakinolide.<sup>75</sup>

These chondramide A analogues were indeed able to block parasite invasion into host cells (Table 3).<sup>76</sup> Although they lack specificity for parasite vs. host actin other analogues might be able to disturb actin dynamics in parasites without harming the host.



### Pladienolide B

The relevance of NPs stems also from the fact that occasionally compounds are isolated that lead to the discovery of biological processes which offer new opportunities in the treatment of diseases. Recent examples include NPs that bind to components of the spliceosome. In retrospect this is not too surprising since the spliceosome is responsible for the correct removal of introns from mRNA precursors in eukaryotic cells.<sup>77</sup> The spliceosome is assembled from five *small nuclear ribonucleoproteins* (snRNP; U1, U2, U4, U5, U6) and associated protein factors. The intron removal requires sequence recognition. This is guided by certain motifs in the introns like branch sequences and polypyrimidine regions. It seems that the U2 snRNP has a key role in that it pairs with the branch sequence. This snRNP itself is composed of the U2 snRNA, U2 snRNP specific proteins (sm proteins) and two splicing factors SF3a and SF3b. The latter is a multiprotein complex made up






Scheme 11 Summary of the synthetic strategy to chondramide A (124).



#### SAR summary:



Scheme 12 Synthesis of various 2-methoxy- $\beta$ -tyrosine analogues and their incorporation into the chondramide A system. Summary of the SAR for the chondramide/jasplakinolide class of cyclodepsipeptides illustrated on the structure of jasplakinolide (123).

Table 3 Biological activities of chondramide A and the analogues on human primary foreskin fibroblast (HFF) cells together with growth inhibitory data on *T. gondii*

Compound	R	EC <sub>50</sub> (HFF) [ $\mu\text{M}$ ]	EC <sub>50</sub> ( <i>T. gondii</i> ) [ $\mu\text{M}$ ]
124	OH	0.109	0.51
140b	Me	0.027	0.53
140c	OMe	0.066	0.69
140d	F	0.029	0.32
140e	$\text{NO}_2$	0.040	0.61
140f	$\text{NH}_2$	0.057	0.66
140g	$\text{CH}_2\text{OH}$	0.052	0.74
140h	$(\text{CH}_2)_2\text{OH}$	0.059	0.60
140i	CN	0.027	0.38
140j	$\text{CONH}_2$	1.424	>45
140k	Ph	0.213	1.34



of splicing associated proteins (SAP) 155, 145 and 130. These are also known as SF3b1, which seems to be the target of pladienolide B,<sup>78</sup> SF3b2 and SF3b3. The exons can be joined in various ways as a result of alternative splicing. Thus, one gene can code for several proteins. Erroneous splicing is a key feature of cancer cells. Accordingly, inhibition of splicing appears as a promising anticancer strategy, at least for some types of cancer.

So far several natural products are known to inhibit the splicing process (Fig. 12). They include polyketides of the pladienolide family, like the natural products pladienolide B (**141**), pladienolide D (**142**)<sup>79</sup> and FD-895 (**144**).<sup>80</sup> Molecules like GEX1A (herboxidiene) (**145**)<sup>81</sup> have a side chain similar to the one in pladienolide B. Another group of spliceosome inhibitors represented by FR901464 (**146**)<sup>82</sup> features two pyran rings. A related compound is thailanstatin (**148**).<sup>83</sup> The Eisai company, which had discovered the pladienolides, early on described the structure of the carbamate derivative E7107 (**143**). This compound is also active indicating that modifications at C7 are tolerated. It even advanced to human trials.<sup>84,85</sup> A dose-limiting study revealed common side effects of antitumor compounds, for example, nausea, vomiting and diarrhoea. However, since some patients also suffered from bilateral optic neuritis (visual disturbance due to inflammation of the optic nerve) the human trials were discontinued.

In order to discover improved and simpler SF3b inhibitors, SAR studies are clearly important. For FR901464 a range of analogues have been prepared by the groups of Koide and Webb. For example on meayamycin (**149**), an analogue that has two methyl groups at C1, SAR studies revealed the importance of the (*Z*)-pentenamide side chain with the allylic acetate, the methyl groups on the pyran ring, the diene region and the spiro epoxide (Fig. 13).<sup>86</sup> Changes or omissions on these parts produced much less active compounds. Related analogues, called sudemycins, were developed by Webb *et al.*<sup>87</sup> These analogues also contained the pharmacophore common to FR901464 and the pladienolides, namely the spiro epoxide at a certain distance to the allylic acetate.<sup>88</sup> In some cell lines these analogues achieved IC<sub>50</sub> values in the low micromolar range.

Since pladienolide appears to be more challenging from a synthetic point of view, fewer analogues are known. A simplified pladienolide analogue **154** was made by Webb *et al.*<sup>89</sup> It lacks the methyl groups at C10, C15 and C22 as well as the 3-OH (Fig. 14). While this compound turned out to be essentially inactive, the more hydrophobic compound **153** (21-*O*-*tert*-butyldimethylsilyl) was at least moderately active (IC<sub>50</sub> 10.7 μM, SK-MEL-2, melanoma cell line). This result clearly underscores the role of methyl groups as contributors to hydrophobic binding and as conformational control elements. Research by Chandrasekhar showed that aryl analogues of pladienolide B, like **155**, with a truncated side chain are also active.<sup>90</sup> However, this seems not to be in line with the pharmacophore model of Webb. Compound **156** with a truncated side chain lacking the epoxide and with the wrong configur-




Fig. 12 Structures of some important spliceosome inhibitors.

ation at C7 was also completely inactive.<sup>91</sup> Pladienolide D analogue **157** lacking the 6-OH turned out to be quite active.<sup>92</sup>

In the course of the elucidation of the side chain stereochemistry of FD-895 several diastereomers were prepared.<sup>93</sup> With 17-*epi* derivative **158** an analogue was found that was almost 20 times more active than FD-895 itself. As can be seen with the less active cyclopropyl analogue **159**, the epoxide does contribute to the biological activity. Studies on pladienolide-herboxidiene hybrid compounds highlighted the importance of the methyl substituent in the pyran ring and the role of the






Fig. 13 Key structural feature important for the activity of FR901464 and analogues inspired by FR901464.

hydroxyl group in the side chain.<sup>94</sup> However, one should say that the findings partly contradict themselves. Thus whereas **160** with a free hydroxyl group is inactive, the free hydroxyl group of **161** seems to be crucial.

Focusing on the synthesis of pladienolides, the most challenging seems to be creation of building blocks that contain the C6–C7 diol and the formation of the macrolactone. One strategy utilized by Kotake is the asymmetric dihydroxylation of (*Z*)-alkene **162**.<sup>95</sup> An esterification of the derived alkenoic acid **164** with alkenol **165** provided substrate **166** for a ring-closing metathesis (Scheme 13). The Burkart group first prepared monoprotected diol **169** by a Brown allylation of aldehyde **168**. Thereafter the tertiary alcohol at C6 was created *via* addition of MeMgBr to the alkoxyketone derived from **169**. As before, the ring was closed *via* rcm (Scheme 13).

The chelation controlled Grignard addition to an  $\alpha$ -alkoxyketone was also used by Ghosh *et al.*<sup>96</sup> However, here the synthesis of the required ketone started with divinylmethanol **174**. Opening of the derived epoxide **175** with the dienolate of **176** and asymmetric reduction of the keto ester **177** gave diol derivative **178** (Scheme 14). Oxidation and reaction with the Grignard reagent led to enoate **179**. This was further elaborated to macrolactone **181**.

A very simple and clever way to set up the C6–C7 region was put forward by Chandrasekhar.<sup>90</sup> Thus, a Sharpless asym-






Fig. 14 Pladienolide B analogues and SAR information gathered from them. Compounds **153** and **154** (ref. 89), compound **155** (ref. 90), compound **156** (ref. 91), compound **157** (ref. 92), compounds **158** and **159** (ref. 93), and compounds **160** and **161** (ref. 94).






**Kotake (2007):** dihydroxylation, rcm**Burkart (2012):** Brown allylation, addn. of MeMgBr to alkoxyketone

**Scheme 13** Synthetic strategies to create building blocks containing the C<sub>6</sub>,C<sub>7</sub>-diol.

metric epoxidation (SAE) led to epoxide **182** (Scheme 15). Its hydrolytic opening followed by protection of the diol gave compound **183**. As can be seen, further elaboration of **183** to acid **185** did require a number of steps. In this work also an rcm strategy came to use for the creation of the macrolactone.

Our own approach to the pladienolide core was different but not without problems. Since most of the rcm approaches


**Ghosh (2012):** alkylation of β-keto ester with epoxide, asymm. reduction

**Scheme 14** Other strategies to create building blocks containing the C<sub>6</sub>,C<sub>7</sub>-diol.

gave the macrolactone only in moderate yield we opted for a classical macrolactonization approach. We also recognized the match of the stereocenter in (*R*)-(-)-linalool with that of C<sub>6</sub> in the pladienolides. To combine the subunits for the seco acid, a HWE reaction was planned followed by reduction of the enone. Accordingly, (*R*)-(-)-linalool was converted to aldehyde **186** which upon an acetate aldol reaction furnished hydroxy acid derivative **187** (Scheme 15). Manipulation of the car-



Maier (2011, 2014): intermolecular HWE, Shiina macrolactonization



**Scheme 15** Unexpected synthesis of 7-*epi*-pladienolide B (199) due to Mitsunobu acetylation under retention of configuration. MNBA = 2-methyl-6-nitrobenzoic anhydride.

boxylic function and the double bond delivered aldehyde **188**. Addition of lithiated phosphonate **189** and oxidation gave rise to keto phosphonate **190**. Under optimized conditions phosphonate **190** underwent a HWE reaction with aldehyde **191** providing enone **192**. Cyclization of the derived seco acid **193** with the Shiina reagent<sup>97</sup> afforded macrocyclic enone **194** in good yield. Unfortunately, a reduction of the enone under Luche conditions gave the 7-*epi*-alcohol **195**. In the course of the synthesis of pladienolide B analogue **156** (Scheme 15), after a Stille cross-coupling with phenyltributylstannane, the C7 allylic alcohol was acetylated under Mitsunobu conditions.<sup>91</sup> However, as we later found out, the Mitsunobu reaction had occurred with retention of configuration. Thus, acetylation of **195** either under Mitsunobu or classical acetylation conditions gave the same allylic acetate **196**. Cleavage of the MEM and TBS protecting groups delivered core structure **197**. A final Stille cross-coupling with vinylstannane **198** furnished pladienolide B analogue **199**.<sup>98</sup> Its <sup>1</sup>H NMR spectrum showed distinct differences to that from pladienolide B (**141**).


Since it was not possible to reduce the enone in the macrocyclic lactone **194** in the desired way, attempts were made to reduce the enone function on an acyclic precursor. After some trials we found that the chelation controlled reduction of enone **192** delivered the desired allylic alcohol **200** as the major diastereomer (Scheme 16). In a similar manner to that for the 7-*epi* analogue, ester **201** was converted to macrolactone **204** and then to pladienolide B (**141**). The biological evaluation of both compounds revealed a dramatic effect of the configuration at C7. Thus, whereas pladienolide B was highly active ( $\text{IC}_{50} = 7.5 \text{ nM}$ , L929 mouse fibroblast cells), the 7-*epi*-epimer **199** was devoid of any activity.<sup>98</sup> This analogue showed that an acetate or carbamate at C7 with the correct configuration is an essential part of the pharmacophore.

## Function-oriented synthesis (FOS)

The idea of function-oriented synthesis is to circumvent some inherent disadvantages of biologically active NPs. Thus, often they are difficult to obtain from natural sources, in particular if they originate from the marine environment. If their structures are highly complex, they are generally not amenable to total synthesis in larger amounts. Also, in many cases they are not suitable for direct use in humans before some chemical modifications. The ultimate goal of FOS is the design of simpler analogues of NPs where the activity is optimized towards the intended application. At the same time the analogues should allow for straightforward syntheses.<sup>99</sup> The concept of FOS is kind of obvious and trivial. It is similar to DTS but the emphasis here is on function. The analogue of a FOS programme might be much simpler and structurally much different from the NP. The Wender group demonstrated this strategy with the synthesis of several bryostatin analogues. The bryostatins comprise 20 marine macrolides, which were isolated from the bryozoan *Bugula neritina*.<sup>100</sup> They are polyketides featuring three pyran rings and several stereocenters.



Maier (2014): intermolecular HWE, Shiina macrolactonization




Scheme 16 Synthesis of pladienolide B (**141**) via chelation controlled reduction of enone **192**.

They essentially have the same macrocyclic core structure but most of them differ in the substituents at C7 and C20.

The bryostatins are characterized by a range of biological activities, but prevalent is their ability to modulate the activity of protein kinase C. This leads to inhibition of cell growth and angiogenesis. So far several syntheses of bryostatins were reported.<sup>101</sup> The shortest one, the synthesis of bryostatin 7


(**207**), requires 36 steps in total (TS) with 20 steps for the longest linear sequence (LLS) (Scheme 17).<sup>102</sup> Based on the notion that the relevant pharmacophoric regions include the upper lipophilic A and B rings plus the polar carbonyl and hydroxyl groups at C1, C19 and C26, respectively, the Wender group synthesized many highly potent but simpler bryostatin analogues. Among the most potent derivatives was macro-lactone **210** (Scheme 17). Esterification of acid **209** with alcohol **208** followed by macrocyclization *via* intramolecular acetal formation gave analogue **210** (32 TS), (17 LLS).<sup>103</sup> The design of these analogues was probably inspired by the good availability of the lower fragment **208**.<sup>104</sup> This allowed for connection with various simplified upper fragments.<sup>105</sup>

Although not extensively covered in this account, one should mention the discovery of eribulin mesylate whose design was inspired by the marine-derived natural product halichondrin B. This rather complex polyketide is a potent




Scheme 17 Synthesis of bryostatin analogue **210** from the lower fragment **208** and the diol derivative **209**.





**Scheme 18** Synthesis of eribulin mesylate (**216**) on the production scale.

antitumor agent which works by inhibition of microtubule dynamics. In the course of synthetic studies using a convergent approach it was discovered that the biological activity resides in the right part of the molecule. Among simplified macrolactone, macrocyclic ether, macrolactam and macrocyclic ketone analogues, the latter was found to be the best compromise.<sup>106,107</sup> Eribulin mesylate (**216**) has been approved for clinical use in 2010 in the USA (Scheme 18). Key fragments were prepared using a chiron approach starting with D-glucuronolactone (**211**) and D-(-)-gulonolactone (**212**). In addition, epoxide **215** served as a starting material. First the C0–C1 bond was formed by addition of the anion of **213** to the aldehyde derived from **214**. The macrocyclic ring was closed between C13–C14 using a Nozaki–Hiyama–Kishi (NHK) reaction. Altogether, three key bond formations relied on the NHK coupling (C19–C20, C26–C27, C13–C14). This case nicely underscores the high level of organic synthesis in some pharmaceutical companies.



**Fig. 15** Design of affinity-based probes for kinases with cysteine in the binding region. The cellular inhibition of EGFR autophosphorylation in A431 cells after stimulation with EGF is given for the most active compound **218**.

Taking the benzolactone hypothemycin (**218**) as a lead, the Winsinger group designed simpler mimetics that react irreversibly with certain kinases that have an exposed cysteine in the so-called DFG binding motif. Thus, analogues like **218** feature the resorcylic acid part as a hinge binder and an electrophilic trap to address the cysteine (Fig. 15).<sup>108</sup>

## Biology-oriented synthesis (BIOS)

The principle of BIOS is to use scaffolds contained in NPs as starting points for the synthesis of compound libraries.<sup>109</sup> This concept is based on the notion that NP scaffolds and possibly substructures of NP core structures define privileged structures. In other words, evolutionarily formed NP scaffolds match highly conserved subfolds of ligand sites.

For the selection of suitable NP-like scaffolds the Waldmann group conceived two complementary approaches. The first is a hierarchical structural organization of scaffolds contained in NPs. After removal of side chains that do not contain rings, in each truncation step one peripheral ring is removed according to certain guidelines. This way, parent–child relationships are generated with the parent being the simpler structure. This leads to tree-like branches of NP scaffolds. One such branch is shown in Fig. 16. Representative NPs for each scaffold include digitoxigenin (**219**), the aglycon of the cardiac glycoside digitoxin, dehydroepiandrosterone (DHEA, **220**), the tetradecahydrophenanthrene-type diterpene klysimplexin T<sup>110</sup> (**221**), nakamurolo A<sup>111</sup> (**222**), and gabosine A<sup>112</sup> (**223**).

If one argues that a parent (simpler) scaffold to a child scaffold which contains an active representative might also show some activity if properly functionalized, then a parent scaffold might form the basis of a compound library. Of particular interest are branches that contain gaps, meaning core






Fig. 16 Example of a branch from the NP scaffold tree (left column). The parent is always the simpler structure in a chain. Representative NPs for each scaffold are shown in the right column.


structures in a sequence that do not have a corresponding NP. Software to visualize the hierarchical organization of NPs is freely available.<sup>113</sup> Of particular use is this kind of clustering if biological activity data are available for molecules, representing scaffolds in the branches. In this case, so-called virtual scaffolds located between a complex and a simpler one for both of which compounds are known with related activity should be ideally suited for library development.

A second approach put forward by the Waldmann group starts with proteins. In this protein structure similarity cluster-

ing (PSSC), protein folds are clustered according to their similarity. The hypothesis is that a ligand for a member of a protein cluster might also bind to other members of a cluster.<sup>114</sup> Therefore, it should be possible to use such NP scaffolds, their parents or grand parents for library construction to address members of a protein cluster that might be relevant for medicinal application.


Recent examples from the Waldmann group are still based on the BIOS approach but at the same time are substantially chemistry driven.<sup>115,116</sup> This means that substructures of NPs are used as guidelines which can be constructed or functionalized by novel and simple chemistry. For example, taking the tetrahydroisoquinoline NP noscapine (224) as a lead, a compound collection of tetrahydroisoquinolines 226 was prepared by reacting iminium ions 225 with acetylene nucleophiles (Scheme 19). Not surprisingly, several derivatives were found that, like 227, interfere with microtubule polymerization. In the assays performed, alkyne 227 showed the highest activity.

If a class of NPs comprises a large number of members they also should be promising leads for analogue syntheses. For example, iridoids are widespread in nature and display a range of biological activities.<sup>117</sup> The Waldmann group utilized an asymmetric [3 + 2]-cycloaddition between azomethine ylides, generated from glycine imines 229, and pyranones 230 (Scheme 20). The latter are available from furfuryl alcohols *via* oxidative rearrangement. In the presence of a Cu(I) salt, the ligand 231 and DBU, the cycloaddition proceeded with good diastereoselectivities.<sup>118</sup> Out of a collection of 115



Scheme 19 Synthesis of a tetrahydroisoquinoline collection.






**Scheme 20** Synthesis of a library of fused heterocycles **232** inspired by the structure of iridoids.

derivatives, nine were able to inhibit Wnt signalling with an IC<sub>50</sub> below 10 μM. The Wnt pathway plays a role in cell differentiation and stem-cell renewal. Other representatives from this collection turned out to be inhibitors of the hedgehog signalling pathway.

## Complexity to diversity (CtD)

Due to the fact that NPs have unique shapes, ring systems and diverse functional groups they are in principle interesting starting points for the preparation of NP analogues. The problem is to selectively address the various functional groups of a NP in order to avoid the formation of complex mixtures. According to Hergenrother, who coined the term complexity to diversity (CtD) one can distinguish two categories.<sup>119</sup> One strategy entails reactions on a single functional group to generate a new structure. A classical singular example is the preparation of ansa-steroids by a domino Diels–Alder/retro-Diels–Alder reaction between ergosterol derivatives and propynal.<sup>120,121</sup> For example, steroid **235** could be opened to macrocycle **237** utilizing this concept (Scheme 21).<sup>122</sup> A second strategy addresses several functional groups on a NP to create new derivatives.


Selective modifications of the diterpene abietic acid (**238**) enabled the construction of 84 different compounds.<sup>123</sup> The



**Scheme 21** Synthesis of macrocyclic paracyclophane **237** from diene **235** via a Diels–Alder/retro-Diels–Alder sequence.


initial challenge is to differentiate the two double bonds and the carboxylic group. This is possible by dihydroxylation. From diol **240** a new ring system can be obtained by oxidative cleavage followed by intramolecular aldol condensation (Scheme 22).

Manipulation of the B-ring is possible after protection of the diol in **240** as a cyclic carbonate. Ring expansion was illustrated with cyclopropanation followed by electrocyclic ring opening induced by AgBF<sub>4</sub> in MeOH (Scheme 23). Ring system **245** resulted from dihydroxylation of the double bond, oxidative cleavage and intramolecular aldol reaction.




**Scheme 22** Synthesis of tricyclic compound **242** by the ring distortion strategy.






Scheme 23 Conversion of alkene 240 to compounds 244 and 245.



Scheme 24 CtD strategies applied to the alkaloid quinine (246).

The CtD strategy can be applied to all kinds of natural products. For example, the alkaloid quinine (246) was also subjected to controlled structural changes (Scheme 24).<sup>124</sup> Thus, treatment of 246 with thionochloroformate resulted in ring cleavage between N1 and C2. The putative intermediate thiocarbonate rearranged to the polycyclic *S*-alkyl thiocarbonate



Scheme 25 CtD-type manipulations on fumagillol (251).

247 whose structure could be confirmed by X-ray crystallography. On the other hand, acid induced Hoffmann elimination led to piperidine 248. After protection of the amine, Patis methylenation of the keto function followed by ring-closing metathesis resulted in octahydroisoquinoline derivative 250 (Scheme 24). Further unique structures were accessible by Grignard additions to the quinoline ring of 246.

Several related functional groups in a molecule like an enone or epoxide can be engaged in a domino sequence with a bis-nucleophile to furnish derivatives with increased structural complexity. An illustrative case is the remodeling of fumagillol (251) (Scheme 25). In the presence of the Lewis acid La(OTf)<sub>3</sub> and an arylamine a 5-*exo*-bis-epoxide opening takes place to give annulated pyrrolidine derivatives 252.<sup>125</sup> A subsequent reaction of the bicyclic compounds 252 with DDQ (1 equiv.) in the presence of a nucleophile led to a stereo-selective addition resulting in complex NP analogues 253. In this example, a terpene is transformed to alkaloid-like compounds.

The CtD strategy appears to be promising and worthwhile for easily available natural products. However, so far it seems that no useful biological activity has been reported for any of the CtD derived NP analogues.



## Hybrid molecules

The principle of this concept is to combine partial or whole structures of molecules to create new, possibly more active, molecular entities.<sup>126</sup> It is a quite simple and, in certain ways, naive approach. But in biology this concept is widespread. This is very often the case when the subunits of a molecule undertake different functions, for example redox processes or target binding, like DNA recognition. Thus, in the anthracycline antibiotic daunorubicin (**257**), three functional units can be identified (Fig. 17): a DNA intercalating domain, a domain interacting with the enzyme topoisomerase II, and finally, the sugar part that binds to the minor groove. In fact, the aglycon has 70–100 times lower antitumor activity than daunorubicin. A more complicated structure which can be considered a hybrid molecule is calicheamicin  $\gamma_1$ .<sup>127</sup>

The many natural products that are made up of identical parts may also be classified as hybrid molecules. Some prominent examples, including rhizopodin (**258**), blepharocalyxin D (**259**), incarvilleatone (**260**), blennolide G (**261**), cephalostatin 1 (**262**) and chaetocin A (**263**), are shown in Fig. 18.

The dopamine derivative aspongamide A (**265**) is an example of a trimeric natural product. It is made up of three *N*-acetyl-dopamine (**264**) molecules (Fig. 19). This compound was isolated from the insect *Aspongopus chinensis*, which is found in southern China.<sup>128</sup> Dried bodies of this insect are used as traditional medicine for the treatment of pain, stomach problems and kidney diseases. This insect was investigated with the aim to find natural products that are active against chronic kidney disease (CKD). This disease is a consequence of diabetes. The trimer **265** turned out to inhibit smad3 phosphorylation, which plays a role in pathogenesis of CKD.

The use of hybrid molecules is one of the pillars of bio-conjugation. For example, target identification of a bioactive molecule often relies on constructs where the small molecule is linked *via* a T-piece adapter to a photoreactive group and biotin.<sup>129</sup> In these cases it is known from the outset that the biological activity of such constructs is usually reduced, but




Fig. 17 Structure of daunorubicin with its three functional subunits.




Fig. 18 Some examples of dimeric natural products. In cases where the subunits are less obvious they are colored.








Fig. 19 Aspongamide A (259) as an example of a trimeric natural product.

the purpose of course is different. One such hybrid molecule is depicted in Fig. 20. It contains the microbial product GEX1A (herboxidiene, **145**). This NP was originally isolated as a herbicide.<sup>130</sup> Later it turned out to also have antitumor activity *in vivo*. Its side chain is quite similar to that of the polyketide pladienolide B (**141**), a compound that also displays potent antitumor activity. As pladienolide B targets the SF3b1 subunit of the spliceosome, it is not too surprising that construct **267** led to the discovery that GEX1A also targets a subunit of SF3b.<sup>131</sup> In particular, the development of click reactions and chemical ligation methods facilitated the construction of hybrid molecules.

According to Meunier three categories of hybrid molecules can be distinguished (Fig. 21).<sup>132</sup> It might be that both parts of the hybrids act on one target. This does not need to be the same binding pocket.

A case in point is the so-called trioxaquinones that contain an aminoquinoline and a 1,2,4-trioxane. The latter is inspired by the natural product artemisinin (**268**) which is a powerful anti-malarial drug. The conjugate PA1103/SAR116242 (**270**) and related molecules are considered “double-edged sword” drugs (Fig. 22). Thus, the aminoquinoline sector can stack with heme, whereas the trioxane part can alkylate heme after reductive activation. Indeed these hybrids are active on chloroquine-resistant strains of *Plasmodium falciparum*. Compound **270** was eventually selected as an antimalarial drug candidate for further development.<sup>133</sup>

Hybrid molecules of the second category act with each subunit on different and non-related targets. If the linker is




Fig. 20 Hybrid **261** that led to the discovery that GEX1A targets the spliceosome.




Fig. 21 Categories of hybrid molecules according to their mode of action. (a) Both parts act on the same target (not necessarily on the same site); (b) each part acts on a different target; (c) both parts bind to one target at closely related binding sites.






Fig. 22 Trioxaquinones like 270 are patterned after artemisinin (268) and chloroquine (269). Both parts act on heme of the parasite.

cleaved in the biological system, the hybrids are like dual prodrugs. The parts of the hybrid molecule may also act at the same time on two connected targets, as illustrated with category (c). Examples include fragment based drug discovery<sup>134</sup> or DNA ligands, like the above-mentioned daunorubicin. If the exact mode of action of a hybrid is not known, it is of course difficult to categorize it according to Fig. 21.

Macrocycles frequently have been turned into hybrid molecules. An option is to borrow a side chain from an active molecule and to attach it to a macrocyclic core. For example, some of the 16-membered macrophelides are able to induce apoptosis in human lymphoma U937 cells. In an attempt to enhance their potency, hybrid macrophelides were designed that contain the side chain of the epothilones (Scheme 26).<sup>135</sup> The synthesis of hybrid 272 started from homoallylic alcohol 273, which was extended by three esterification reactions to triester 274. A ring-closing metathesis reaction and simple functional group manipulations led to NP analogue 272. This compound showed significantly higher apoptosis-inducing activity than the parent macrophelides.

A more dramatic modification is the replacement of a region in a macrocycle with a section from another NP. This is best done by total synthesis. The Kirschning group designed hybrids that contain the aromatic core of geldanamycin (275) and the maytansine aliphatic part (Scheme 27).<sup>136</sup> Geldanamycin (275) and maytansine (279) are representatives of the ansamycin antibiotics. The subfamily of the maytansinoids consists of several ansamitocins as well as maytansine. The geldanamycin<sup>137</sup> subfamily includes macbecin I (276), herbimycin (277), and reblastin (278). While the maytansinoids share the same ring size for the macrolactam with the geldanamycins, they differ in their mode of action. Whereas the maytansinoids bind to and block the polymerization of tubulin, the cytotoxicity of the geldanamycins is due to their interaction with the heat shock protein Hsp90 $\alpha$ . Therefore, the synthesis

Scheme 26 Design and synthesis of macrophelide–epothilone hybrids.





of hybrids like 281 seemed to be of interest and to make sense.

The aliphatic C1–C12 part 286 could be obtained from acrolein in a sequence of 12 steps utilizing asymmetric allylation and aldol reactions to create C–C bonds and the stereocenters (Scheme 27). A Heck coupling between vinyl iodide 282 and building block 286 was followed by an intramolecular copper-catalyzed amidation reaction. After the generation of the hydroxyketone functionality at C7–C9 a biotransformation attached the carbamoyl group at 7-OH.

Due to the isopropoxy groups that could not be removed, hybrid 281 exists as a mixture of separable atropisomers. The minor isomer displayed significant activity against cancer cell lines (KB-3-1: 2.2  $\mu\text{g mL}^{-1}$ ; SKOV-3: 4.5  $\mu\text{g mL}^{-1}$ ). This activity might be connected to a mechanism that is different from the ansamycins. On the one hand 281 does not bind to Hsp90 $\alpha$ . On the other hand its conformation is different from that of the maytansinoids. This example shows that it is difficult to predict reliably at the outset of a design the activity of a hybrid molecule.


The replacement of a larger section of a macrolactone with a fragment obtained from an amino acid is another strategy





**Scheme 27** Design and chemical synthesis of maytansine–geldanamycin hybrids.

for obtaining hybrids of a NP. For example, latrunculin derived hybrid macrocyclic carbamates **287** were prepared using this rationale (Fig. 23).<sup>138</sup> So far, however, biological data for these and other compounds are lacking.



**Fig. 23** Hybrid structures designed based on latrunculin A.

Molecules that bind to microtubules represent an important class of anticancer agents. Such molecules can stop cell cycle progression either by breaking up or stabilizing microtubules. Based on combretastatin A-4 (**288**), which causes disruption of microtubules through binding to  $\beta$ -tubulin, and pironetin (**22**), which inhibits tubulin assembly by targeting  $\alpha$ -tubulin, the Marco group designed hybrids consisting of combretastatin A-4 (CoA4, **288**) and simplified pironetin analogues linked together *via* a tether of variable length (Fig. 24).<sup>139</sup> The simplified pironetins **291** and **292** contain at least the essential  $\alpha$ -pyrone moiety. Compound **292** additionally features the 7-OH and the 9-OMe groups. The idea was to find improved compounds that can either bind  $\alpha$ - or  $\beta$ -tubulin. Even though the exact distance between the two binding sites is not known, compounds might be found that address both sites simultaneously.

As described above (Scheme 2) the secondary alcohol functions were generated by Brown allylation reactions on the corresponding aldehydes. CoA4 derivatives equipped with a linker were prepared from CoA4 (**288**) by etherification with  $\omega$ -bromo esters to give esters **289a–d** followed by saponification to the acids **290a–d**. A Yamaguchi esterification served to prepare the hybrids **293a–d** and **294a–d** (Fig. 24).

The screening for cytotoxicity was performed with two tumor cell lines (human colon adenocarcinoma HT-29 and breast adenocarcinoma MCF-7 cell lines) and, for comparison, with the normal human embryonic kidney cell line HEK-293. As it turned out all compounds were active in the low to medium micromolar range including the parent NPs (Table 4). Compounds **289b**, **289c**, **289d** and **290d** were active in both cell lines. Worth mentioning are compounds *ent*-**293a**, **294c**, **289c**, **289d** and **290d** that show pronounced selectivity for the tumor cell lines. Among the hybrids **293a–d** and **294a–d** that differ from each other in the length of the connecting spacer, the ones with a ten-carbon chain show maximum activity (**293c** and **294c**). For all hybrids it seems that there is no simultaneous binding to both  $\alpha$ - and  $\beta$ -tubulin. Comparing the hybrids **293a–c** and their enantiomers to the pironetin analogue points to the fact that the cytotoxicity mainly originates from the CoA4 region. This example shows that a rational design of hybrids remains rather difficult.






Fig. 24 Structures of pironetin analogue/combetrestatin hybrids and the corresponding precursors.

## Biosynthesis inspired synthesis of NP analogues

In many cases the biosynthesis of a NP is known. At least hypotheses regarding key transformations do exist in general. This is often provided whenever an alkaloid or terpene with a novel structure is published.<sup>140,141</sup> For NPs from microorganisms a lot is known about the biosynthetic machinery and the genes that code for the structure of a NP. This is the case with polyketides from bacteria and partly from fungi.<sup>142</sup> These genes are arranged in a sequence of modules. A loading module catches the starting carboxylic acid derivative, which is bound to the biosynthesis machinery as a thioester. Every module extends the chain by two carbon atoms *via* a Claisen condensation. The modules may contain additional domains that perform typical steps common to fatty acid biosynthesis, namely, reduction of the 3-ketoester to a 3-hydroxy ester (KR =

Table 4 Cytotoxicity of the hybrids from Fig. 24 against various cell lines given as IC<sub>50</sub> values [μM]<sup>a</sup>

Compound	HT-29	MCF-7	HEK-293
CoA4 ( <b>288</b> )	4.2	1	25
Pironetin ( <b>22</b> )	8	18	46
<b>293a</b>	12	52	39
<b>293b</b>	32	>300	80
<b>293c</b>	10	>300	>300
<b>293d</b>	107	>300	>300
<i>ent-293a</i>	3.5	17	114
<i>ent-293b</i>	19	>300	>300
<i>ent-293c</i>	38	69	59
<i>ent-293d</i>	64	>300	72
<b>294a</b>	15.4	31	22
<b>294b</b>	44	>300	>300
<b>294c</b>	2.9	5.6	22
<b>294d</b>	50.8	21	81
<b>289a</b>	60.1	10.4	121
<b>290a</b>	50	2.9	67
<b>289b</b>	3.5	9.6	9.6
<b>290b</b>	16	17	>300
<b>289c</b>	8	3	>300
<b>290c</b>	103	5	>300
<b>289d</b>	5	9.6	>300
<b>290d</b>	1.9	4.4	39
<b>291</b>	109	>300	35
<i>ent-291</i>	81	109	119
<b>292</b>	25.4	2.5	>300


<sup>a</sup>Compounds with high toxicity towards both tumoral cell lines are marked in italics.

keto reductase), elimination of water to give an enoate (DH = dehydratase) and conjugate reduction of the enoate (ER = enoyl reductase). Typical extender units are malonyl-CoA and methylmalonyl-CoA. Some other ones are known such as methoxymalonyl-CoA or allylmalonyl-CoA. Thus, by simply looking at the structures of the seco acid of a polyketide macrolactone, the domains, besides the ACP and KS that perform the Claisen condensations, can be predicted. This is shown in Fig. 25 for the immunosuppressive FK506 (**295**).<sup>143</sup> Module 4 uses allylmalonyl-CoA, and modules 7 and 8 use methoxymalonyl-CoA as extender units.


### Mutasynthesis

The detailed knowledge about the biosynthesis of polyketides can be exploited for the synthesis of NP analogues. In the case of mutasynthesis a mutant organism is generated where the synthesis of a natural building block has been blocked by deletion of the corresponding gene. Frequently, this refers to the starting unit of a polyketide which typically is very different from the extender units.<sup>144</sup> Using mutasynthesis, the Kirschnig group produced a range of geldanamycin derivatives that by total synthesis would not be available so efficiently.<sup>145</sup> Thus, by feeding various 3-aminobenzoic acids to the mutant *S. hygroscopicus* K390-61-1, in which the synthesis of the natural starting unit was blocked, a range of novel geldanamycin analogues could be obtained (Scheme 28). The acids shown were accepted well and the process could be scaled-up. One limitation of mutasynthesis lies in the fact that only





**Fig. 25** Biosynthesis of the polyketide FK506 (tacrolimus). Domains in modules might be inactive (red), non-functional (blue) or completely absent. KS, ketoacyl synthase (performs Claisen condensation; prior to the Claisen condensation the growing chain is attached to KS, the extender unit to ACP); AT, acyl transferase; DH, dehydratase; ER, enoyl reductase; KR, keto reductase; ACP, acyl carrier protein.




**Scheme 28** Mutagenesis of nonbenzoquinone geldanamycin analogues by mutagenesis. The analogues were obtained by feeding the acids to the blocked mutant of (K390-61-1) of *S. hygroscopicus*.

certain building blocks are accepted by the acyltransferase (AT) of the loading module.

Mutagenesis can be combined with chemical synthesis (semisynthesis) if building blocks are incorporated that allow for subsequent selective transformations. This has been illustrated with the synthesis of ansamitocin analogues.<sup>146</sup> For example, feeding of 3-amino-4-bromobenzoic acid (309) to the AHBA (-) blocked mutant of *Actinosynnema pretiosum* produced the ansamitocin P3 derivative 310. This compound









**Scheme 29** Mutasythesis followed by chemical modification. Both compounds were quite active [ $IC_{50}$  (pmol mL<sup>-1</sup>), KB-3-1 cell line, **310**: 0.46, **311**: 0.67].

turned out to be a suitable substrate for Pd-catalyzed cross-coupling reactions (Scheme 29).<sup>147</sup>

In case an extender unit in a polyketide significantly differs from the standard acetate and propionate building blocks, mutasythesis of analogues is possible by knocking out the synthesis of the unusual extender unit and adding substituted malonyl-CoA extender units. For example, the allyl group at C21 of the immunosuppressive FK506 is incorporated into the polyketide chain *via* the allyl malonyl-CoA extender unit **317** (Scheme 30). Investigations by Moore *et al.* showed that it is synthesized from 3-ethylacrylate **314**. Reductive carboxylation is followed by introduction of the terminal double bond. For the final dehydrogenation the gene *tcsD* is responsible. By knocking out the *tcsB* gene that is involved in the synthesis of this building block (Claisen condensation to **313**), a deletion mutant of *Streptomyces* sp. KCTC 11604BP was generated and used for the mutasythesis of some FK506 analogues.<sup>148</sup> By feeding *trans*-2-hexenoic acid (**320**), 4-methylpentanoic acid (**322**) and 4-fluorocrotonic acid (**324**) the known analogue **321** and the new analogues **323** and **325** were obtained. Biological testing showed 36-methyl-FK506 (**323**) to exhibit improved neurite outgrowth activity. However, the *in vivo* production levels turned out to be rather modest (0.06 mg mL<sup>-1</sup> for **323**).

In order to replace parts of a NP that originate from common extender units, pathway engineering is necessary. For example, a range of geldanamycin analogues could be produced by replacing the original acyltransferase (AT) domains in various modules of the geldanamycin polyketide synthase (GdmPKS) with a malonyl AT domain from the rapamycin PKS.



**Scheme 30** Mutasythesis of FK506 analogues **321**, **323**, and **325** by feeding the acids **320**, **322**, and **324**, respectively, to the *ΔtcsB* strain of *Streptomyces* sp. KCTC 11604BP.

Thus, changing AT1 which incorporates normally methylmalonyl-CoA led to analogue **326** (Fig. 26).<sup>149</sup> Other obtained analogues are also shown. In all cases production yields were






Fig. 26 Geldanamycin analogues obtained by AT substitutions in the GdmPKS. AT1 incorporates chain atoms 13 and 14, AT4 atoms 7 and 8, AT5 atoms 5 and 6, and AT7 atoms 1 and 2. Values for Hsp90  $K_d$  (nM) are given in brackets.


sufficient for the characterization of the analogues and activity assays. Analogue 329 displayed a four-fold enhancement of the binding affinity for Hsp90.

If all the genes required for the synthesis of an unusual extender unit are engineered into a producer where the particular biosynthesis of the extender unit to be replaced is blocked, then novel NP analogues can be obtained as well. The group of Moore cloned the three genes anIF, anIG and anIE that produce the isobutyrylmalonyl-CoA building block in an ansalactam producer strain into the integrative vector pSET152. Gene expression was placed under the control of the constitutive ermE\* promoter in vector pLD6. These plasmids were conjugated into the mutant *Streptomyces* sp. KCTC 11604BP  $\Delta$ tcsB so that background production of FK506 was eliminated.<sup>150</sup> With the gene tcsD, which is responsible for dehydrogenation, still intact, good production levels of 36-methyl-FK506 (323) could be realized (Scheme 31).


### Silent genes

The sequencing of bacterial genomes and the associated genetic analysis did provide some stunning facts. Thus, it is possible to predict the stereochemistry of secondary hydroxyl functions from the gene sequence of the corresponding keto reductases and the stereochemistry of methyl-bearing centers.<sup>151</sup> Another finding was that in many polyketide synthases some genes are silent. That is, some enzymes are not operative. The exact reason for this is unknown. In order to shed some light on this phenomenon the total synthesis of NPs encoded by the complete polyketide synthases is a worthwhile task. This has recently been done for the macrolide soraphen A.<sup>152</sup> For some time this NP was a promising antitumor and antifungal compound due to its ability to inhibit eukaryotic acetyl-coenzyme A carboxylase. According to the genetic analysis, modules 5 and 8 contain inactive domains (Fig. 27).<sup>153,154</sup> Module 5 should produce a saturated section. Since the ER is not active an enoate double bond should remain (C8–C9). However soraphen A (335) has a double bond at C9–C10. This could either be the result of a deconjugation on the enoate or of a postketide transformation. Module 8 is lacking an ER and features inactive KH and DH domains.





**Fig. 27** Structure of soraphen and arrangement of modules 1–8. The domains for modules 2, 5 and 8 are indicated together with the structure of the seco acid **338** corresponding to the full functional domains. KS = keto synthase, AT = acyl transferase, DH = dehydratase, KR = keto reductase, ER = enoyl reductase, TE = thioesterase.



**Scheme 32** Key transformations in the synthesis of the paleo-soraphens A and B.

Based on the structure of soraphen A and the gene sequence, Kalesse *et al.* prepared the so-called paleo-soraphens A (**339**) and B (**340**) (Scheme 32). First, pentenal **341** was converted *via* an organocatalytic  $\alpha$ -hydroxylation to building block **342**. A cross-metathesis between **342** and **343** followed by hydrogenation delivered the C11–C17 part **345**. The C3–C10 region **349** containing an array of five vicinal stereocenters could be constructed from Roche aldehyde **347** which was elongated on both sides using an Evans aldol reaction and a Marshall reaction, respectively. The vinyl iodide function resulted from hydrozirconation/iodination of the corresponding terminal alkyne. For the coupling of aldehyde **345** with vinyl iodide **349** a Nozaki–Hiyama–Kishi reaction came to use. After oxidation of the resulting alcohols (2 : 1 mixture), enone **350** was obtained. A chelation-controlled reduction [Zn(BH<sub>4</sub>)<sub>2</sub>, Et<sub>2</sub>O, –55 °C, 90%, d.r. > 25 : 1] delivered the *anti*-

stereochemistry at C11/C12. Methylation and reductive ester cleavage furnished the advanced building block **351**.

From there, six routine steps including chain extension by Wittig reaction and Shiina macrolactonization led to paleo-soraphen A (**339**). One additional step, namely the hydrogenation of the double bond of **351** in the presence of the Crabtree catalyst, was required to reach paleo-soraphen B (**340**).

Biological tests showed both compounds to have much lower antifungal activity (Table 5). The cytotoxic activity was also almost gone.

The mode of action of the two paleo-soraphens was subsequently probed by impedance profiling. The principle of this method is that molecules with a similar mode of action will show similar time-dependent impedance curves. A hierarchical cluster analysis indicated paleo-soraphen A to be in close proximity to soraphen A. In contrast, paleo-soraphen B turned





**Table 5** Antifungal activity of the paleo-soraphens in comparison with soraphen A (**325**) given as IC<sub>50</sub> values (μg mL<sup>-1</sup>)

Compound	<i>Pythium debaryanum</i>	<i>Botrytis cinerea</i>	<i>Mucor hiemalis</i>
Paleo-soraphen A ( <b>339</b> )	0.4	>40	21
Paleo-soraphen B ( <b>340</b> )	>40	>40	16
Soraphen A ( <b>335</b> )	0.045	0.0035	0.0006

up in a cluster with camptothecin, a well-known topoisomerase inhibitor.


While in the case at hand this concept did not lead to highly potent compounds it appears promising for the selection of targets for synthesis programmes. If this observation should be general, it might also reveal regions of NPs that are important for the biological activity. Thus, the parts which originate from modules with silent domains would then be important for activity.

### Propionate-scanning

It is obvious that the molecular scaffold and substituents on a NP determine its affinity and selectivity to a cellular target. The scaffold together with operating conformational effect secures directionality and distance of functional groups that are involved in direct interactions with the target protein. Many NPs are characterized by a molecular built. This means that they are assembled from small building blocks as in the case of peptides, polyketides or terpenes. In a way they can be considered natural oligomers. However, in general it is not known what determines the selection of a building block for a certain position. To what extent this is random or driven by evolution remains largely unclear. In peptides an alanin scan is often used to address the importance of amino acids at certain positions.<sup>155,156</sup>

In polyketides two main building blocks, acetate and propionates, are common. A propionate results in a methyl substituent on the backbone. There are polyketides that consist of only one type of building block. For example, zearalenone (**353**) and curvularin (**355**) are solely acetate based NPs (Fig. 28). On the other hand erythronolide B (**356**) only contains propionate building blocks.

Typically polyketide NPs are made up of both types of building blocks. Thus, the antitumor compound dictyostatin (**357**) is constructed from seven acetates and six propionates (Fig. 29). It is also worth mentioning that plants and microorganisms themselves produce NP analogues in large numbers. Thus, with all natural product classes rather similar compounds have been isolated over the years. In fact, it is nowadays not that easy to discover really novel natural products. With regard to polyketides, epothilone A (**358**) and B (**1**) represent a pair of macrolactones that only differ in one methyl group. The myxobacterium strain *Sporangium cellulorum* produces 22 mg mL<sup>-1</sup> epothilone A (**358**) and 11 mg mL<sup>-1</sup> epothi-



**Fig. 28** Structures of natural products that are only made up of one type of building block. Key polyketide intermediates for zearalenone and curvularin are also shown. Red bold bonds indicate the acetate carbons. The 6-OH in **356** originates from an oxidation.

lone B (**1**).<sup>157</sup> The additional methyl group (propionate instead of acetate) in epothilone B results in about ten times stronger antitumor activity. In the case of the statins also several similar compounds are known that only differ in a few substituents. While compactin (**359**), isolated from the fungus *Penicillium citrinum*, has too many side effects, lovastatin (mevacor) (**360**) from *Aspergillus terreus* and pravastatin (mevalotin) (**361**) from the bacterium *Nocardia autotrophica* are in clinical use. Due to their inhibitory effect on HMG reductase, the statins are used as cholesterol lowering drugs. However, one should mention that designed NP mimetics like atorvastatin have a higher market share. These examples underscore the importance of substituents for biological activity.

Our goal in this project was to investigate the role of an additional methyl group in the simple lactones zearalenone (**353**) and curvularin (**355**). The plan was not to use genetic engineering but rather organic synthesis. We wanted to con-






Fig. 29 Structure of dictyostatin (**357**), a mixed polyketide, and examples of NP analogues produced by nature.

sider biosynthetic aspects, meaning that the methyl group would be positioned on the scaffold where it would make sense from a biosynthesis point of view. Thus, replacing the second acetate with propionate led to propionate analogues like **362** and **363** (Fig. 30).<sup>158</sup> In tests for cytotoxicity several analogues showed activity in the low micromolar range, comparable with or better than zearalenone itself. Thermal shift assays performed on Hsp90 revealed a rough correlation of the  $T_m$ -shifts<sup>159</sup> with the  $IC_{50}$  values. A higher  $T_m$ -shift means stronger binding to Hsp90.




Fig. 30 Zearalenone analogues with a propionate as a second building block. The  $IC_{50}$  values against L929 mouse fibroblasts and the  $T_m$ -shift values against Hsp90 are given in brackets.


Shifting the methyl group to the third acetate produced rather weak analogues (Fig. 31). Thus, it seems that a methyl group at this position interferes with binding to target proteins relevant for the cytotoxic effects. The corresponding aryl methyl ethers showed even weaker activity.

A propionate at position four (5'-Me) led to a rather interesting analogue **367** (Fig. 32). As evaluated by a thermal shift assay it binds to fewer kinase targets than zearalenone.<sup>160</sup> Binding to Hsp90 was completely blocked by the additional methyl group. Instead, analogue **367** was found to bind to human carbonyl reductase 1 (CBR 1) in the presence of the oxidized cofactor NADP<sup>+</sup> ( $IC_{50}$  = 210 nM).


Shifting the methyl group to the next acetate (3'-Me) also produced an analogue **368** that was more active in the cell proliferation assay than zearalenone (**353**) (Fig. 33).<sup>161</sup> The dissociation constant of **368** for Hsp90 was determined with 130 nM.

While we could make these analogues, each substitution pattern required a separate synthetic strategy. Key steps for each group of analogues are summarized in the following schemes. Thus, the synthesis of compounds of type **362** started with the Frater alkylation product **372** which *via* alkynoate **374** was converted to Weinreb amide **375** (Scheme 33). Grignard addition eventually led to alkenol **376**. Its esterification with acid **377** under Mitsunobu conditions furnished ester **378**. Ring-closing metathesis [Grubbs 2<sup>nd</sup>, toluene, 80 °C, 5 h (85%)] and deprotection steps led to analogue **362**.






**Fig. 31** Zearalenone analogues with a propionate as the third building block. The  $\text{IC}_{50}$  values against L929 mouse fibroblasts are given in brackets. Here  $T_m$ -shift values were not determined.



**Fig. 33** Zearalenone analogues with a propionate as the fifth building block. The  $\text{IC}_{50}$  values against L929 mouse fibroblasts are given in brackets.




$T_m$ -shifts against some kinases:

	PIM	SLK	LOK	Hsp90
zearalenone ( <b>353</b> )	3.0	4.4	4.6	3.3
analogue <b>367</b>	2.2	3.5	-	-

**Fig. 32** Zearalenone analogue **367** does not bind to Hsp90 and is less strong than other kinases according to DSF. DSF = differential scanning fluorometry.


For benzolactones of type **364** an rcm-strategy could be used as well (Scheme 34). In the assembly of the aliphatic building block **381** an Evans aldol reaction between 5-hexenal and carboxylic acid derivative **379** set the stereochemistry at C7'. In some of these analogues, the C7' center was prone to epimerization.

A different strategy was employed for the synthesis of analogue **367**. Thus, alkynol **383** resulting from a Marshall-Tamaru reaction served as the precursor for alkenol **384** (Scheme 35).<sup>160</sup> Its hydroboration and coupling with vinyl




**Scheme 33** Synthesis strategy towards zearalenone analogue **362**.






Scheme 34 Synthesis strategy towards zearalenone analogue 358. ADDP = azodicarboxylic acid dipiperidide.



Scheme 35 Synthesis strategy towards zearalenone analogue 367.



Scheme 36 Synthesis strategy towards zearalenone analogue 368.

iodide 385 led to hydroxy acid 387. Macrolactone formation under Mitsunobu conditions followed by routine steps delivered zearalenone analogue 367.

Yet another approach was chosen for analogue 368 (Scheme 36). Here aldehyde 390 was converted to propargylic alcohol 391. Protection and hydrogenation gave the building block 392. The derived sulfone 393 was combined with aldehyde 394 *via* Julia–Kocienski olefination. Carboxylation followed by protecting group manipulation and macrolactonization furnished benzolactone 368. However, even for simple compounds like the polyketide zearalenone the synthesis effort is substantial. Even though we just studied



zearalenone analogues it can be concluded that methyl groups modulate biological activity. This is also known from classical drug discovery programmes.<sup>162</sup> But with analogue 367 we found one case where the additional methyl group redirects the molecule to another target protein. Such cases seem quite interesting. A similar scanning could be performed with hydroxyl functions or combinations of methyl and hydroxyl groups.

## Conclusions

This review shows that natural product analogues can be prepared by organic synthesis. However, even for simple compounds like, for example, the polyketide zearalenone, the synthesis effort required is substantial. But it is less a problem how we can prepare a certain molecule, but rather a problem concerning which molecules chemists should prepare. After the era of combinatorial chemistry the goal should be to prepare as few as possible molecules to achieve a molecule with the desired properties. Thus, some kind of preselection seems highly desirable in order to avoid the bottleneck organic synthesis. However, even in case the target is known, reliable and accurate docking of flexible NPs or similar compounds has so far appeared impossible. Thus, for many years to come, organic chemists will work like hunters and gatherers. While prediction of the biological activity of a designed molecule will remain difficult, strategies based on genomics appear promising.<sup>163</sup> This would require chemists to acquire the relevant skills. Another option would be to use a brute force approach and to put some emphasis on the development of docking software. Thus, with a suitable structure generator that would generate virtual NP analogues based on biosynthesis rules, subsequent docking might be able to suggest promising compounds for synthesis. Until then the design and synthesis of NP analogues will rely largely on trial and error, supplemented with hunches and experience of scientists. In addition, one should not forget the role of serendipity for discovery and the advancement of science.

## Acknowledgements

Financial support by the Federate State of Baden-Württemberg, the Fonds der Chemischen Industrie, and in particular the DFG is gratefully acknowledged. Part of this work was carried out within the framework of EU COST Action CM0804 (Chemical Biology with Natural Products). I also thank Dr Florenz Sasse (HZI Braunschweig) and his team for performing cellular assays with our compounds for many years.

## Notes and references

- (a) D. J. Newman and G. M. Cragg, *J. Nat. Prod.*, 2012, **75**, 311; G. M. Cragg and D. J. Newman, *Biochim. Biophys.*

- Acta, Gen. Subj.*, 2013, **1830**, 3670(b) B. B. Mishra and V. K. Tiwari, *Eur. J. Med. Chem.*, 2011, **46**, 4769.
- (a) A. L. Harvey, *Drug Discovery Today*, 2008, **13**, 894; (b) C. Cordier, D. Morton, S. Murrison, A. Nelson and C. O'Leary-Steele, *Nat. Prod. Rep.*, 2008, **25**, 719; (c) K. Grabowski, K.-H. Baringhaus and G. Schneider, *Nat. Prod. Rep.*, 2008, **25**, 892; (d) N. I. Vasilevich, R. V. Kombarov, D. V. Genis and M. A. Kirpichenok, *J. Med. Chem.*, 2012, **55**, 7003.
- A. Ganesan, *Curr. Opin. Chem. Biol.*, 2008, **12**, 306.
- E. Kellenberger, A. Hofmann and R. J. Quinn, *Nat. Prod. Rep.*, 2011, **28**, 1483.
- L. Ruddigkeit, L. C. Blum and J.-L. Reymond, *J. Chem. Inf. Model.*, 2012, **53**, 56.
- M. Awale, R. van Deursen and J.-L. Reymond, *J. Chem. Inf. Model.*, 2013, **53**, 509.
- M. Gütlein, A. Karwath and S. Kramer, *J. Cheminf.*, 2012, **4**, 7, DOI: 10.1186/1758-2946-4-7.
- A. M. Virshup, J. Contreras-Garcia, P. Wipf, W. Yang and D. N. Beratan, *J. Am. Chem. Soc.*, 2013, **135**, 7296.
- R. M. Wilson and S. J. Danishefsky, *J. Org. Chem.*, 2006, **71**, 8329.
- For a review, see: A. M. Szpilman and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2010, **49**, 9592.
- J. P. Nandy, M. Prakesch, S. Khadem, P. T. Reddy, U. Sharma and P. Arya, *Chem. Rev.*, 2009, **109**, 1999.
- For recent reviews, see: (a) K.-H. Altmann, F. Z. Gaugaz and R. Schiess, *Mol. Diversity*, 2011, **15**, 383; (b) M. J. Edelman and M. Shvartsbeyn, *Clin. Lung Cancer*, 2012, **13**, 171; (c) S. Kaiser, J. J. Muller, P. E. Froehlich, S. Cristina Baggio Gnoatto and A. M. Bergold, *Anti-Cancer Agents Med. Chem.*, 2013, **13**, 1057.
- K. B. Kim and C. M. Crews, *Nat. Prod. Rep.*, 2013, **30**, 600.
- P. M. Wright, I. B. Seiple and A. G. Myers, *Angew. Chem., Int. Ed.*, 2014, **53**, 8840–8869.
- One can find countless cases for DTS in the literature, for example on dictyostatin: (a) W. Zhu, M. Jiménez, W.-H. Jung, D. P. Camarco, R. Balachandran, A. Vogt, B. W. Day and D. P. Curran, *J. Am. Chem. Soc.*, 2010, **132**, 9175; (b) I. Paterson, G. J. Naylor, N. M. Gardner, E. Guzmán and A. E. Wright, *Chem. – Asian J.*, 2011, **6**, 459; (c) L. L. Vollmer, M. Jiménez, D. P. Camarco, W. Zhu, H. N. Daghestani, R. Balachandran, C. E. Reese, J. S. Lazo, N. A. Hukriede, D. P. Curran, B. W. Day and A. Vogt, *Mol. Cancer Ther.*, 2011, **10**, 994; (d) J. Gallon, J. Esteban, S. Bouzbouz, M. Campbell, S. Reymond and J. Cossy, *Chem. – Eur. J.*, 2012, **18**, 11788.
- For some reviews, see: (a) M. D. Burke and S. L. Schreiber, *Angew. Chem., Int. Ed.*, 2004, **43**, 46; (b) T. E. Nielsen and S. L. Schreiber, *Angew. Chem., Int. Ed.*, 2008, **47**, 48; (c) R. J. Spandl, A. Bender and D. R. Spring, *Org. Biomol. Chem.*, 2008, **6**, 1149; (d) C. Cordier, D. Morton, S. Murrison, A. Nelson and C. O'Leary-Steele, *Nat. Prod. Rep.*, 2008, **25**, 719; (e) W. R. J. D. Galloway, A. Isidro-Llobet and D. R. Spring, *Nat. Commun.*, 2010, **1**, 1; (f) C. Serba and N. Winssinger, *Eur. J. Org. Chem.*, 2013, 4195.



- 17 For example: (a) C. Chen, X. Li, C. S. Neumann, M. M. C. Lo and S. L. Schreiber, *Angew. Chem., Int. Ed.*, 2005, **44**, 2249; (b) S. Su, D. E. Acquilano, J. Arumugasamy, A. B. Beeler, E. L. Eastwood, J. R. Giguere, P. Lan, X. Lei, G. K. Min, A. R. Yeager, Y. Zhou, J. S. Panek, J. K. Snyder, S. E. Schaus and J. A. Porco Jr., *Org. Lett.*, 2005, **7**, 2751; (c) V. Duplan, C. Serba, J. Garcia, G. Valot, S. Barluenga, M. Hoerlé, M. Cuendet and N. Winssinger, *Org. Biomol. Chem.*, 2014, **12**, 370.
- 18 A. Fürstner, D. Kirk, M. D. B. Fenster, C. Aiessa, D. De Souza, C. Nevado, T. Tuttle, W. Thiel and O. Müller, *Chem. – Eur. J.*, 2007, **13**, 135.
- 19 Y. Kashman, A. Groweiss and U. Shmueli, *Tetrahedron Lett.*, 1980, **21**, 3629.
- 20 S. Kudrimoti, S. A. Ahmed, P. R. Daga, A. E. Wahba, S. I. Khalifa, R. J. Doerksen and M. T. Hamann, *Bioorg. Med. Chem.*, 2009, **17**, 7517.
- 21 K. A. El Sayed, M. A. Khanfar, H. M. Shallal, A. Muralidharan, B. Awate, D. T. A. Youssef, Y. Liu, Y.-D. Zhou, D. G. Nagle and G. Shah, *J. Nat. Prod.*, 2008, **71**, 396.
- 22 A. Fürstner, D. De Souza, L. Turet, M. D. B. Fenster, L. Parra-Rapado, C. Wirtz, R. Myott and C. W. Lehmann, *Chem. – Eur. J.*, 2007, **13**, 115.
- 23 I. Paterson, D. Y. K. Chen, M. J. Coster, J. L. Aceña, J. Bach and D. J. Wallace, *Org. Biomol. Chem.*, 2005, **3**, 2431.
- 24 For a review, see: J. Pietruszka, *Angew. Chem., Int. Ed.*, 1998, **37**, 2629.
- 25 A. B. Smith III, C. A. Risatti, O. Atasoylu, C. S. Bennett, J. Liu, H. Cheng, K. TenDyke and Q. Xu, *J. Am. Chem. Soc.*, 2011, **133**, 14042.
- 26 M. Carda, J. Murga, S. Díaz-Oltra, J. García-Pla, J. Paños, E. Falomir, C. Trigili, J. F. Díaz, I. Barasoain and J. A. Marco, *Eur. J. Org. Chem.*, 2013, 1116.
- 27 A. F. Petri, F. Sasse and M. E. Maier, *Eur. J. Org. Chem.*, 2005, 1865.
- 28 Among the benzolactones, radicicol served as a prominent lead structure for analogue synthesis because of its binding to Hsp90: (a) E. Moulin, V. Zoete, S. Barluenga, M. Karplus and N. Winssinger, *J. Am. Chem. Soc.*, 2005, **127**, 6999; (b) X. Lei and S. J. Danishefsky, *Adv. Synth. Catal.*, 2008, **350**, 1677; (c) R. R. A. Kitson and C. J. Moody, *J. Org. Chem.*, 2013, **78**, 5117.
- 29 The benzolactone enamides might be considered a subclass of the resorcylic acid lactones. These are covered in the following review: N. Winssinger and S. Barluenga, *Chem. Commun.*, 2007, 22.
- 30 For some reviews regarding the biology of V-ATPases, see: (a) E. J. Bowman and B. J. Bowman, *J. Bioenerg. Biomembr.*, 2005, **37**, 431; (b) K. W. Beyenbach and H. Wiczorek, *J. Exp. Biol.*, 2006, **209**, 577; (c) M. Huss and H. Wiczorek, *J. Exp. Biol.*, 2009, **212**, 341; (d) M. Perez-Sayans, J. M. Somoza-Martin, F. Barros-Angueira, J. M. G. Rey and A. Garcia-Garcia, *Cancer Treat. Rev.*, 2009, **35**, 707.
- 31 X.-S. Xie, D. Padron, X. Liao, J. Wang, M. G. Roth and J. K. De Brabander, *J. Biol. Chem.*, 2004, **279**, 19755.
- 32 For total syntheses, see: (a) A. Bhattacharjee, O. R. Seguil and J. K. De Brabander, *Tetrahedron Lett.*, 2001, **42**, 1217; (b) K. C. Nicolaou, D. W. Kim and R. Baati, *Angew. Chem., Int. Ed.*, 2002, **41**, 3701; (c) Q. Su and J. S. Panek, *J. Am. Chem. Soc.*, 2004, **126**, 2425; (d) S. S. Palimkar and J. Uenishi, *Org. Lett.*, 2010, **12**, 4160.
- 33 A. F. Petri, A. Bayer and M. E. Maier, *Angew. Chem., Int. Ed.*, 2004, **43**, 5821.
- 34 Other groups also used transannular pyran formation: (a) F. Hilli, J. M. White and M. A. Rizzacasa, *Tetrahedron*, 2011, **67**, 5054; (b) Y.-H. Jung, Y.-J. Kim, J. Lee and J. Tae, *Chem. – Asian J.*, 2007, **2**, 656.
- 35 (a) K. C. Nicolaou, D. W. Kim, R. Baati, A. O'Brate and P. Giannakakou, *Chem. – Eur. J.*, 2003, **9**, 6177; (b) S. S. Palimkar, J. Uenishi and H. Ii, *J. Org. Chem.*, 2011, **77**, 388.
- 36 M. Bauer and M. E. Maier, *Org. Lett.*, 2002, **4**, 2205.
- 37 C. Herb and M. E. Maier, *J. Org. Chem.*, 2003, **68**, 8129.
- 38 C. Herb, A. Bayer and M. E. Maier, *Chem. – Eur. J.*, 2004, **10**, 5649.
- 39 C. Herb, F. Dettner and M. E. Maier, *Eur. J. Org. Chem.*, 2005, 728.
- 40 J. Ritschel, F. Sasse and M. E. Maier, *Eur. J. Org. Chem.*, 2007, 78.
- 41 S. Lebreton, X.-S. Xie, D. Ferguson and J. K. De Brabander, *Tetrahedron*, 2004, **60**, 9635.
- 42 For the synthesis of some other salicylilalamide analogues, see: (a) Y. Sugimoto, K. Konoki, M. Murata, M. Matsushita, H. Kanazawa and T. Oishi, *J. Med. Chem.*, 2009, **52**, 798; (b) S. Tang and K. L. Erickson, *J. Nat. Prod.*, 2008, **71**, 898.
- 43 S. Lebreton, J. Jaunbergs, M. G. Roth, D. A. Ferguson and J. K. De Brabander, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 5879.
- 44 K. H. Müller, G. A. Spoden, K. D. Scheffer, R. Brunnhöfer, J. K. De Brabander, M. E. Maier, L. Florin and C. P. Muller, *Antimicrob. Agents Chemother.*, 2014, **58**, 2905.
- 45 J. A. Hall, B. R. Kusuma, G. E. L. Brandt and B. S. J. Blagg, *ACS Chem. Biol.*, 2014, **9**, 976.
- 46 For a recent review, see: J. Franke, S. Eichner, C. Zeilinger and A. Kirschning, *Nat. Prod. Rep.*, 2013, **30**, 1299.
- 47 L. Jundt, H. Steinmetz, P. Luger, M. Weber, B. Kunze, H. Reichenbach and G. Höfle, *Eur. J. Org. Chem.*, 2006, 5036.
- 48 V. V. Vintonyak and M. E. Maier, *Angew. Chem., Int. Ed.*, 2007, **46**, 5209.
- 49 A. Fürstner, M. Bindl and L. Jean, *Angew. Chem., Int. Ed.*, 2007, **46**, 9275–9278.
- 50 M. Fouché, L. Rooney and A. G. M. Barrett, *J. Org. Chem.*, 2012, **77**, 3060.
- 51 B. R. Kusuma, G. E. L. Brandt and B. S. J. Blagg, *Org. Lett.*, 2012, **14**, 6242.



- 52 For a recent review, see: A. Fürstner, *Angew. Chem., Int. Ed.*, 2013, **52**, 2794.
- 53 (a) V. V. Vintonyak and M. E. Maier, *Org. Lett.*, 2008, **10**, 1239; (b) V. V. Vintonyak, M. Calà, F. Lay, B. Kunze, F. Sasse and M. E. Maier, *Chem. – Eur. J.*, 2008, **14**, 3709.
- 54 M. Bindl, L. Jean, J. Herrmann, R. Müller and A. Fürstner, *Chem. – Eur. J.*, 2009, **15**, 12310.
- 55 V. V. Vintonyak, B. Kunze, F. Sasse and M. E. Maier, *Chem. – Eur. J.*, 2008, **14**, 11132.
- 56 A. E. Wright, J. C. Botelho, E. Guzmán, D. Harmody, P. Linley, P. J. McCarthy, T. P. Pitts, S. A. Pomponi and J. K. Reed, *J. Nat. Prod.*, 2007, **70**, 412.
- 57 (a) W. Youngsaye, J. T. Lowe, F. Pohlki, P. Ralifo and J. S. Panek, *Angew. Chem., Int. Ed.*, 2007, **46**, 9211; (b) S. K. Woo, M. S. Kwon and E. Lee, *Angew. Chem., Int. Ed.*, 2008, **47**, 3242–3244; (c) D. W. Custar, T. P. Zabawa and K. A. Scheidt, *J. Am. Chem. Soc.*, 2008, **130**, 804; (d) H. Fuwa, S. Naito, T. Goto and M. Sasaki, *Angew. Chem., Int. Ed.*, 2008, **47**, 4737–4739; (e) O. A. Ulanovskaya, J. Janjic, M. Suzuki, S. S. Sabharwal, P. T. Schumacker, S. J. Kron and S. A. Kozmin, *Nat. Chem. Biol.*, 2008, **4**, 418; (f) I. Paterson and N. A. Miller, *Chem. Commun.*, 2008, 4708; (g) X. Guinchard and E. Roulland, *Org. Lett.*, 2009, **11**, 4700; (h) Y. Cui, W. Tu and P. E. Floreancig, *Tetrahedron*, 2010, **66**, 4867; (i) H. Fuwa, A. Saito and M. Sasaki, *Angew. Chem., Int. Ed.*, 2010, **49**, 3041; (j) A. K. Ghosh, K. A. Shurrush and Z. L. Dawson, *Org. Biomol. Chem.*, 2013, **11**, 7768.
- 58 For the most recent one, see: G. V. M. Sharma, S. V. Reddy and K. V. S. Ramakrishna, *Org. Biomol. Chem.*, 2012, **10**, 3689.
- 59 (a) H. Fuwa, A. Saito, S. Naito, K. Konoki, M. Yotsu-Yamashita and M. Sasaki, *Chem. – Eur. J.*, 2009, **15**, 12807; (b) D. W. Custar, T. P. Zabawa, J. Hines, C. M. Crews and K. A. Scheidt, *J. Am. Chem. Soc.*, 2009, **131**, 12406; (c) Y. Cui, R. Balachandran, B. W. Day and P. E. Floreancig, *J. Org. Chem.*, 2012, **77**, 2225; (d) H. Fuwa, M. Kawakami, K. Noto, T. Muto, Y. Suga, K. Konoki, M. Yotsu-Yamashita and M. Sasaki, *Chem. – Eur. J.*, 2013, **19**, 8100; (e) H. Fuwa, T. Noguchi, M. Kawakami and M. Sasaki, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 2415.
- 60 For a review, see: G. S. Bagavananthem Andavan and R. Lemmens-Gruber, *Mar. Drugs*, 2010, **8**, 810.
- 61 Y.-Y. Xu, C. Liu and Z.-P. Liu, *Curr. Org. Synth.*, 2013, **10**, 67.
- 62 (a) B. Kunze, R. Jansen, F. Sasse, G. Höfle and H. Reichenbach, *J. Antibiot.*, 1995, **48**, 1262; (b) R. Jansen, B. Kunze, H. Reichenbach and G. Höfle, *Liebigs Ann.*, 1996, 285.
- 63 (a) T. M. Zabriskie, J. A. Klocke, C. M. Ireland, A. H. Marcus, T. F. Molinski, D. J. Faulkner, C. Xu and J. C. Clardy, *J. Am. Chem. Soc.*, 1986, **108**, 3123; (b) P. Crews, L. V. Manes and M. Boehler, *Tetrahedron Lett.*, 1986, **27**, 2797.
- 64 A. Tripathi, J. Puddick, M. I. R. Prinsep, M. Rottmann and L. T. Tan, *J. Nat. Prod.*, 2010, **73**, 1810.
- 65 (a) Isolation: P. D. Boudreau, T. Byrum, W.-T. Liu, P. C. Dorrestein and W. H. Gerwick, *J. Nat. Prod.*, 2012, **75**, 1560; (b) Total synthesis: D. Wang, S. Song, Y. Tian, Y. Xu, Z. Miao and A. Zhang, *J. Nat. Prod.*, 2013, **76**, 974.
- 66 See, for example: A. K. Ghosh and D. K. Moon, *Org. Lett.*, 2007, **9**, 2425 and references cited therein.
- 67 T.-S. Hu, R. Tannert, H.-D. Arndt and H. Waldmann, *Chem. Commun.*, 2007, 3942.
- 68 H. Waldmann, T.-S. Hu, S. Renner, S. Menninger, R. Tannert, T. Oda and H.-D. Arndt, *Angew. Chem., Int. Ed.*, 2008, **47**, 6473–6477.
- 69 U. Eggert, R. Diestel, F. Sasse, R. Jansen, B. Kunze and M. Kalesse, *Angew. Chem., Int. Ed.*, 2008, **47**, 6478–6482.
- 70 (a) F. Sasse, B. Kunze, T. M. A. Gronewold and H. Reichenbach, *J. Natl. Cancer Inst.*, 1998, **90**, 1559; (b) L.-G. Milroy, S. Rizzo, A. Calderon, B. Ellinger, S. Erdmann, J. Mondry, P. Verveer, P. Bastiaens, H. Waldmann, L. Dehmelt and H.-D. Arndt, *J. Am. Chem. Soc.*, 2012, **134**, 8480.
- 71 A. Schmauder, S. Müller and M. E. Maier, *Tetrahedron*, 2008, **64**, 6263.
- 72 A. Schmauder, L. D. Sibley and M. E. Maier, *Chem. – Eur. J.*, 2010, **16**, 4328.
- 73 A. Zhdanko, A. Schmauder, C. I. Ma, L. D. Sibley, D. Sept, F. Sasse and M. E. Maier, *Chem. – Eur. J.*, 2011, **17**, 13349.
- 74 For the synthesis of jasplakinolide analogues, see: (a) A. K. Ghosh, Z. L. Dawson, D. K. Moon, R. Bai and E. Hamel, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 5104; (b) L.-G. Milroy, S. Rizzo, A. Calderon, B. Ellinger, S. Erdmann, J. Mondry, P. Verveer, P. Bastiaens, H. Waldmann, L. Dehmelt and H.-D. Arndt, *J. Am. Chem. Soc.*, 2012, **134**, 8480.
- 75 R. Tannert, L.-G. Milroy, B. Ellinger, T.-S. Hu, H.-D. Arndt and H. Waldmann, *J. Am. Chem. Soc.*, 2010, **132**, 3063.
- 76 C. I. Ma, K. Diraviyam, M. E. Maier, D. Sept and L. D. Sibley, *J. Nat. Prod.*, 2013, **76**, 1565.
- 77 For some reviews, see: (a) S. Bonnal, L. Vigevani and J. Valcárcel, *Nat. Rev. Drug Discovery*, 2012, **11**, 847; (b) S. M. Dehm, *Cancer Res.*, 2013, **73**, 5309; (c) J. Zhang and J. L. Manley, *Cancer Discovery*, 2013, **3**, 1228; (d) A. G. Matera and Z. Wang, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 108.
- 78 A. Yokoi, Y. Kotake, K. Takahashi, T. Kadowaki, Y. Matsumoto, Y. Minoshima, N. H. Sugi, K. Sagane, M. Hamaguchi, M. Iwata and Y. Mizui, *FEBS J.*, 2011, **278**, 4870.
- 79 (a) T. Sakai, T. Sameshima, M. Matsufuji, N. Kawamura, K. Dobashi and Y. Mizui, *J. Antibiot.*, 2004, **57**, 173; (b) T. Sakai, N. Asai, A. Okuda, N. Kawamura and Y. Mizui, *J. Antibiot.*, 2004, **57**, 180.
- 80 M. Seki-Asano, T. Okazaki, M. Yamagishi, N. Sakai, Y. Takayama, K. Hanada, S. Morimoto, A. Takatsuki and K. Mizoue, *J. Antibiot.*, 1994, **47**, 1395.
- 81 B. G. Isaac, S. W. Ayer, R. C. Elliott and R. J. Stonard, *J. Org. Chem.*, 1992, **57**, 7220.



- 82 (a) H. Nakajima, B. Sato, T. Fujita, S. Takase, H. Terano and M. Okuhara, *J. Antibiot.*, 1996, **49**, 1196; (b) H. Nakajima, S. Takase, H. Terano and H. Tanaka, *J. Antibiot.*, 1997, **50**, 96.
- 83 (a) X. Liu, S. Biswas, M. G. Berg, C. M. Antapli, F. Xie, Q. Wang, M.-C. Tang, G.-L. Tang, L. Zhang, G. Dreyfuss and Y.-Q. Cheng, *J. Nat. Prod.*, 2013, **76**, 685; (b) H. He, A. S. Ratnayake, J. E. Janso, M. He, H. Y. Yang, F. Loganzo, B. Shor, C. J. O'Donnell and F. E. Koehn, *J. Nat. Prod.*, 2014, **77**, 1864.
- 84 M. Sato, N. Muguruma, T. Nakagawa, K. Okamoto, T. Kimura, S. Kitamura, H. Yano, K. Sannomiya, T. Goji, H. Miyamoto, T. Okahisa, H. Mikasa, S. Wada, M. Iwata and T. Takayama, *Cancer Sci.*, 2014, **105**, 110.
- 85 S. M. Dehm, *Clin. Cancer Res.*, 2013, **19**, 6064.
- 86 S. Osman, B. J. Albert, Y. Wang, M. Li, N. L. Czaicki and K. Koide, *Chem. – Eur. J.*, 2011, **17**, 895.
- 87 L. Fan, C. Lagisetti, C. C. Edwards, T. R. Webb and P. M. Potter, *ACS Chem. Biol.*, 2011, **6**, 582.
- 88 C. Lagisetti, A. Pourpak, T. Goronga, Q. Jiang, X. Cui, J. Hyle, J. M. Lahti, S. W. Morris and T. R. Webb, *J. Med. Chem.*, 2009, **52**, 6979.
- 89 M. K. Gundluru, A. Pourpak, X. Cui, S. W. Morris and T. R. Webb, *Med. Chem. Commun.*, 2011, **2**, 904.
- 90 V. P. Kumar and S. Chandrasekhar, *Org. Lett.*, 2013, **15**, 3610.
- 91 S. Müller, T. Mayer, F. Sasse and M. E. Maier, *Org. Lett.*, 2011, **13**, 3940.
- 92 K. Arai, S. Buonamici, B. Chan, L. Corson, A. Endo, B. Gerard, M.-H. Hao, C. Karr, K. Kira, L. Lee, X. Liu, J. T. Lowe, T. Luo, L. A. Marcaurelle, Y. Mizui, M. Nevalainen, M. W. O'Shea, E. S. Park, S. A. Perino, S. Prajapati, M. Shan, P. G. Smith, P. Tivitmahaisoon, J. Y. Wang, M. Warmuth, K.-M. Wu, L. Yu, H. Zhang, G.-Z. Zheng and G. F. Keaney, *Org. Lett.*, 2014, **16**, 5560.
- 93 R. Villa, M. K. Kashyap, D. Kumar, T. J. Kipps, J. E. Castro, J. J. La Clair and M. D. Burkart, *J. Med. Chem.*, 2013, **56**, 6576.
- 94 C. Lagisetti, M. V. Yermolina, L. K. Sharma, G. Palacios, B. J. Prigaro and T. R. Webb, *ACS Chem. Biol.*, 2013, **9**, 643.
- 95 R. M. Kanada, D. Itoh, M. Nagai, J. Nijima, N. Asai, Y. Mizui, S. Abe and Y. Kotake, *Angew. Chem., Int. Ed.*, 2007, **46**, 4350.
- 96 A. K. Ghosh and D. D. Anderson, *Org. Lett.*, 2012, **14**, 4730.
- 97 I. Shiina, H. Fukui and A. Sasaki, *Nat. Protocols*, 2007, **2**, 2312.
- 98 S. Müller, F. Sasse and M. E. Maier, *Eur. J. Org. Chem.*, 2014, 1025.
- 99 For the concept and some reviews, see: (a) P. A. Wender, V. A. Verma, T. J. Paxton and T. H. Pillow, *Acc. Chem. Res.*, 2008, **41**, 40; (b) P. A. Wender, *Tetrahedron*, 2013, **69**, 7529; (c) P. A. Wender, *Nat. Prod. Rep.*, 2014, **31**, 433.
- 100 G. R. Pettit, C. L. Herald, D. L. Doubek, D. L. Herald, E. Arnold and J. Clardy, *J. Am. Chem. Soc.*, 1982, **104**, 6846.
- 101 For a review about the synthesis of bryostatins, see: K. J. Hale and S. Manaviyar, *Chem. – Asian J.*, 2010, **5**, 704.
- 102 Y. Lu, S. K. Woo and M. J. Krische, *J. Am. Chem. Soc.*, 2011, **133**, 13876.
- 103 P. A. Wender, J. C. Horan and V. A. Verma, *Org. Lett.*, 2006, **8**, 5299.
- 104 P. A. Wender, J. Baryza, C. E. Bennett, C. Bi, S. E. Brenner, M. O. Clarke, J. C. Horan, C. Kan, E. Lacôte, B. Lippa, P. G. Nell and T. M. Turner, *J. Am. Chem. Soc.*, 2002, **124**, 13648.
- 105 P. A. Wender, J. L. Baryza, S. E. Brenner, B. A. DeChristopher, B. A. Loy, A. J. Schrier and V. A. Verma, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 6721.
- 106 M. J. Yu, W. Zheng, B. M. Seletsky, B. A. Littlefield and Y. Kishi, in *Annual Reports in Medicinal Chemistry*, ed. J. E. Macor, Academic Press, New York, 2011, ch. 14, vol. 46, pp. 227–241.
- 107 M. J. Yu, W. Zheng and B. M. Seletsky, *Nat. Prod. Rep.*, 2013, **30**, 1158.
- 108 C. Zambaldo, K. K. Sadhu, G. Karthikeyan, S. Barluenga, J.-P. Daguier and N. Winssinger, *Chem. Sci.*, 2013, **4**, 2088.
- 109 For some reviews, see: (a) M. Kaiser, S. Wetzel, K. Kumar and H. Waldmann, *Cell. Mol. Life Sci.*, 2008, **65**, 1186; (b) S. Wetzel, R. S. Bon, K. Kumar and H. Waldmann, *Angew. Chem., Int. Ed.*, 2011, **50**, 10800; (c) S. Rizzo and H. Waldmann, *Chem. Rev.*, 2014, **114**, 4621; (d) H. van Hattum and H. Waldmann, *J. Am. Chem. Soc.*, 2014, **136**, 11853.
- 110 B.-W. Chen, C.-H. Chao, J.-H. Su, C.-W. Tsai, W.-H. Wang, Z.-H. Wen, C.-Y. Huang, P.-J. Sung, Y.-C. Wu and J.-H. Sheu, *Org. Biomol. Chem.*, 2011, **9**, 834.
- 111 S. Díaz, J. Cuesta, A. González and J. Bonjoch, *J. Org. Chem.*, 2003, **68**, 7400.
- 112 For a review, see: D. H. Mac, S. Chandrasekhar and R. Grée, *Eur. J. Org. Chem.*, 2012, 5881.
- 113 (a) S. Wetzel, K. Klein, S. Renner, D. Rauh, T. I. Oprea, P. Mutzel and H. Waldmann, *Nat. Chem. Biol.*, 2009, **5**, 581; (b) K. Klein, O. Koch, N. Kriege, P. Mutzel and T. Schäfer, *Mol. Inf.*, 2013, **32**, 964.
- 114 (a) B. M. McArdle, M. R. Campitelli and R. J. Quinn, *J. Nat. Prod.*, 2006, **69**, 14; (b) D. Camp, R. A. Davis, M. Campitelli, J. Ebdon and R. J. Quinn, *J. Nat. Prod.*, 2011, **75**, 72.
- 115 S. Rizzo and H. Waldmann, *Chem. Rev.*, 2014, **114**, 4621.
- 116 See also: I. D. Jenkins, F. Lacrampe, J. Ripper, L. Alcaraz, P. Van Le, G. Nikolakopoulos, P. de Almeida Leone, R. H. White and R. J. Quinn, *J. Org. Chem.*, 2008, **74**, 1304.
- 117 B. Dinda, S. Debnath and R. Banik, *Chem. Pharm. Bull.*, 2011, **59**, 803.
- 118 H. Takayama, Z.-J. Jia, L. Kremer, J. O. Bauer, C. Strohmann, S. Ziegler, A. P. Antonchick and H. Waldmann, *Angew. Chem., Int. Ed.*, 2013, **52**, 12404–12408.
- 119 K. C. Morrison and P. J. Hergenrother, *Nat. Prod. Rep.*, 2014, **31**, 6.





- 120 P. K. Chowdhury, A. Prella, D. Schomburg, M. Thielmann and E. Winterfeldt, *Liebigs Ann. Chem.*, 1987, 1095–1099.
- 121 For a recent application, see: J.-P. Krieger, G. Ricci, D. Lesuisse, C. Meyer and J. Cossy, *Angew. Chem., Int. Ed.*, 2014, **53**, 8705–8708.
- 122 S. Bäurle, T. Blume, A. Mengel, C. Parchmann, W. Skuballa, S. Bäsler, M. Schäfer, D. Sülzle and H.-P. Wrona-Metzinger, *Angew. Chem., Int. Ed.*, 2003, **42**, 3961–3964.
- 123 R. J. Rafferty, R. W. Hicklin, K. A. Maloof and P. J. Hergenrother, *Angew. Chem., Int. Ed.*, 2014, **53**, 220–224.
- 124 R. W. Huigens III, K. C. Morrison, R. W. Hicklin, T. A. Flood Jr., M. F. Richter and P. J. Hergenrother, *Nat. Chem.*, 2013, **5**, 195.
- 125 A. J. Grenning, J. K. Snyder and J. A. Porco, *Org. Lett.*, 2014, **16**, 792.
- 126 For reviews, see: (a) G. Mehta and V. Singh, *Chem. Soc. Rev.*, 2002, **31**, 324; (b) L. F. Tietze and H. P. Bell, *Angew. Chem., Int. Ed.*, 2003, **42**, 3996; (c) K. Suzuki, *Chem. Rec.*, 2010, **10**, 291.
- 127 For a review, see: K. C. Nicolaou, *J. Org. Chem.*, 2009, **74**, 951.
- 128 Y.-M. Yan, J. Ai, Y.-N. Shi, Z.-L. Zuo, B. Hou, J. Luo and Y.-X. Cheng, *Org. Lett.*, 2014, **16**, 532.
- 129 For a review, see: S. Ziegler, V. Pries, C. Hedberg and H. Waldmann, *Angew. Chem., Int. Ed.*, 2013, **52**, 2744.
- 130 B. G. Isaac, S. W. Ayer, R. C. Elliott and R. J. Stonard, *J. Org. Chem.*, 1992, **57**, 7220.
- 131 M. Hasegawa, T. Miura, K. Kuzuya, A. Inoue, S. Won Ki, S. Horinouchi, T. Yoshida, T. Kunoh, K. Koseki, K. Mino, R. Sasaki, M. Yoshida and T. Mizukami, *ACS Chem. Biol.*, 2011, **6**, 229.
- 132 B. Meunier, *Acc. Chem. Res.*, 2007, **41**, 69.
- 133 F. Coslédan, L. Fraisse, A. Pellet, F. o. Guillou, B. Mordmüller, P. G. Kremsner, A. Moreno, D. Mazier, J.-P. Maffrand and B. Meunier, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 17579.
- 134 For some reviews, see: (a) P. J. Hajduk and J. Greer, *Nat. Rev. Drug Discovery*, 2007, **6**, 211; (b) C. W. Murray and D. C. Rees, *Nat. Chem.*, 2009, **1**, 187; (c) D. E. Scott, A. G. Coyne, S. A. Hudson and C. Abell, *Biochemistry*, 2012, **51**, 4990; (d) M. Baker, *Nat. Rev. Drug Discovery*, 2013, **12**, 5.
- 135 Y. Matsuya, T. Kawaguchi, K. Ishihara, K. Ahmed, Q.-L. Zhao, T. Kondo and H. Nemoto, *Org. Lett.*, 2006, **8**, 4609.
- 136 G. Jürjens and A. Kirschning, *Org. Lett.*, 2014, **16**, 3000.
- 137 For a review, see: J. Franke, S. Eichner, C. Zeilinger and A. Kirschning, *Nat. Prod. Rep.*, 2013, **30**, 1299.
- 138 M. Aeluri, B. Dasari and P. Arya, *Org. Lett.*, 2015, **17**, 472; See also: S. K. R. Guduru, R. Jimmidi, G. S. Deora and P. Arya, *Org. Lett.*, 2015, **17**, 480.
- 139 S. Torijano-Gutiérrez, C. Vilanova, S. Díaz-Oltra, J. Murga, E. Falomir, M. Carda and J. A. Marco, *Eur. J. Org. Chem.*, 2014, 2284.
- 140 For some recent examples, see: (a) H. Lou, S. Zheng, T. Li, J. Zhang, Y. Fei, X. Hao, G. Liang and W. Pan, *Org. Lett.*, 2014, **16**, 2696; (b) L. Song, H. Yao and R. Tong, *Org. Lett.*, 2014, **16**, 3740.
- 141 (a) Y. J. Hong and D. J. Tantillo, *J. Am. Chem. Soc.*, 2014, **136**, 2450; (b) M. Isegawa, S. Maeda, D. J. Tantillo and K. Morokuma, *Chem. Sci.*, 2014, **5**, 1555.
- 142 (a) M. A. Fischbach, C. T. Walsh and J. Clardy, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 4601; (b) J. Young and R. E. Taylor, *Nat. Prod. Rep.*, 2008, **25**, 651; (c) C. Hertweck, *Angew. Chem., Int. Ed.*, 2009, **48**, 4688.
- 143 H. Motamedi and A. Shafiee, *Eur. J. Biochem.*, 1998, **256**, 528.
- 144 For some recent reviews, see: (a) A. Kirschning, F. Taft and T. Knobloch, *Org. Biomol. Chem.*, 2007, **5**, 3245; (b) J. Kennedy, *Nat. Prod. Rep.*, 2008, **25**, 25; (c) A. Kirschning and F. Hahn, *Angew. Chem., Int. Ed.*, 2012, **51**, 4012.
- 145 S. Eichner, H. G. Floss, F. Sasse and A. Kirschning, *ChemBioChem*, 2009, **10**, 1801.
- 146 For a review, see: F. Taft, S. Eichner, T. Knobloch, K. Harmrolfs, J. Hermene and A. Kirschning, *Synlett*, 2012, 1416.
- 147 F. Taft, M. Brünjes, H. G. Floss, N. Czempinski, S. Grond, F. Sasse and A. Kirschning, *ChemBioChem*, 2008, **9**, 1057.
- 148 S. Mo, D. H. Kim, J. H. Lee, J. W. Park, D. B. Basnet, Y. H. Ban, Y. J. Yoo, S.-w. Chen, S. R. Park, E. A. Choi, E. Kim, Y.-Y. Jin, S.-K. Lee, J. Y. Park, Y. Liu, M. O. Lee, K. S. Lee, S. J. Kim, D. Kim, B. C. Park, S.-g. Lee, H. J. Kwon, J.-W. Suh, B. S. Moore, S.-K. Lim and Y. J. Yoon, *J. Am. Chem. Soc.*, 2011, **133**, 976.
- 149 K. Patel, M. Piagentini, A. Rascher, Z.-Q. Tian, G. O. Buchanan, R. Regentin, Z. Hu, C. R. Hutchinson and R. McDaniel, *Chem. Biol.*, 2004, **11**, 1625.
- 150 A. Lechner, M. C. Wilson, Y. H. Ban, J.-y. Hwang, Y. J. Yoon and B. S. Moore, *ACS Synth. Biol.*, 2012, **2**, 379.
- 151 (a) A. Kitsche and M. Kalesse, *ChemBioChem*, 2013, **14**, 851; (b) O. Hartmann and M. Kalesse, *Angew. Chem., Int. Ed.*, 2014, **53**, 7335.
- 152 H.-H. Lu, A. Raja, R. Franke, D. Landsberg, F. Sasse and M. Kalesse, *Angew. Chem., Int. Ed.*, 2013, **52**, 13549.
- 153 J. Ligon, S. Hill, J. Beck, R. Zirkle, I. Molnár, J. Zawodny, S. Money and T. Schupp, *Gene*, 2002, **285**, 257.
- 154 S. C. Wenzel, R. M. Williamson, C. Grünanger, J. Xu, K. Gerth, R. A. Martinez, S. J. Moss, B. J. Carroll, S. Grond, C. J. Unkefer, R. Müller and H. G. Floss, *J. Am. Chem. Soc.*, 2006, **128**, 14325.
- 155 Representative examples: (a) Y. Chen, M. Bilban, C. A. Foster and D. L. Boger, *J. Am. Chem. Soc.*, 2002, **124**, 5431; (b) J. Nam, D. Shin, Y. Rew and D. L. Boger, *J. Am. Chem. Soc.*, 2007, **129**, 8747.
- 156 For a review, see: V. J. Hruby, *Nat. Rev. Drug Discovery*, 2002, **1**, 847.



- 157 G. Höfle, N. Bedorf, H. Steinmetz, D. Schomburg, K. Gerth and H. Reichenbach, *Angew. Chem., Int. Ed. Engl.*, 1996, **35**, 1567.
- 158 M. Ugele, F. Sasse, S. Knapp, O. Fedorov, A. Zubriene, D. Matulis and M. E. Maier, *ChemBioChem*, 2009, **10**, 2203.
- 159 F. H. Niesen, H. Berglund and M. Vedadi, *Nat. Protocols*, 2007, **2**, 2212.
- 160 T. J. Zimmermann, F. H. Niesen, E. S. Pilka, S. Knapp, U. Oppermann and M. E. Maier, *Bioorg. Med. Chem.*, 2009, **17**, 530.
- 161 C. Rink, F. Sasse, D. Matulis, A. Zubriene and M. E. Maier, *Chem. – Eur. J.*, 2010, **16**, 14469.
- 162 For reviews, see: (a) C. S. Leung, S. S. F. Leung, J. Tirado-Rives and W. L. Jorgensen, *J. Med. Chem.*, 2012, **55**, 4489; (b) H. Schönherr and T. Cernak, *Angew. Chem., Int. Ed.*, 2013, **52**, 12256–12267.
- 163 J. R. Doroghazi, J. C. Albright, A. W. Goering, K.-S. Ju, R. R. Haines, K. A. Tchalukov, D. P. Labeda, N. L. Kelleher and W. W. Metcalf, *Nat. Chem. Biol.*, 2014, **10**, 963.

